<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3417f51c-7ace-49a1-ab3e-d14de2384c71"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to useÂ ROSUVASTATIN TABLETS safely and effectively. See full prescribing information for ROSUVASTATIN TABLETS.<br/>ROSUVASTATIN tablets, for oral use<br/>Initial U.S. Approval: 2003</title>
   <effectiveTime value="20250228"/>
   <setId root="40c2900e-4659-49ce-ba4b-5df529b3c53b"/>
   <versionNumber value="9"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="544302778" root="1.3.6.1.4.1.519.1"/>
            <name>Zhejiang Yongtai Pharmaceutical Co., Ltd.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="544302778" root="1.3.6.1.4.1.519.1"/>
                  <name>Zhejiang Yongtai Pharmaceutical Co., Ltd.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="544302778"/>
                        <name>Zhejiang Yongtai Pharmaceutical Co., Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-005" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-006" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-007" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-008" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-005" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-006" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-007" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-008" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-005" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-006" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-007" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-008" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-005" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-006" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-007" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="69434-008" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="4a73e4eb-b545-4952-a760-08176c561f33"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250228"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69434-005" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Rosuvastatin Calcium</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>rosuvastatin calcium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="83MVU38M7Q" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ROSUVASTATIN CALCIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="413KH5ZJ73" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ROSUVASTATIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Anhydrous Dibasic Calcium Phosphate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Crospovidone</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Magnesium Stearate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69434-005-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250302"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69434-005-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250302"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA212059" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250302"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Y16</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69434-006" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Rosuvastatin Calcium</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>rosuvastatin calcium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="83MVU38M7Q" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ROSUVASTATIN CALCIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="413KH5ZJ73" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ROSUVASTATIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Anhydrous Dibasic Calcium Phosphate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69434-006-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250302"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69434-006-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250302"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA212059" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250302"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="7" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Y17</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69434-007" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Rosuvastatin Calcium</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>rosuvastatin calcium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="20"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="83MVU38M7Q" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ROSUVASTATIN CALCIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="413KH5ZJ73" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ROSUVASTATIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Anhydrous Dibasic Calcium Phosphate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69434-007-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250302"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69434-007-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250302"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA212059" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250302"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Y19</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="69434-008" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Rosuvastatin Calcium</name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>rosuvastatin calcium</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="40"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="83MVU38M7Q" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ROSUVASTATIN CALCIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="413KH5ZJ73" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ROSUVASTATIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Anhydrous Dibasic Calcium Phosphate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2S7830E561" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69434-008-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250302"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="69434-008-03" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250302"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA212059" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250302"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Y20</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_25c9d6de-f5a3-4621-974c-e55a008952ae">
               <id root="d55d5782-a23a-4d09-9f05-56752a1f91c3"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Indications and Usage (<linkHtml href="#ID_64b2d363-2e31-49a9-9b93-e85b43fc9386">1</linkHtml>)Â  Â  Â  Â  Â  Â  Â  Â  Â  Â 07/2024</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_64b2d363-2e31-49a9-9b93-e85b43fc9386">
               <id root="8adec052-5079-4c26-acb4-dbf637f43b5e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>Rosuvastatin tablets are indicated:<br/>â¢ To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) â¥2 mg/L, and at least one additional CV risk factor.<br/>â¢ As an adjunct to diet to:<br/>Âº Reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.<br/>Âº Reduce LDL-C and slow the progression of atherosclerosis in adults.<br/>Âº Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).<br/>â¢ As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).<br/>â¢ As an adjunct to diet for the treatment of adults with:<br/>Âº Primary dysbetalipoproteinemia.<br/>Âº Hypertriglyceridemia.</paragraph>
               </text>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ROSUVASTATIN TABLETS are an HMG Co-A reductase inhibitor (statin) indicated:<linkHtml href="#ID_64b2d363-2e31-49a9-9b93-e85b43fc9386"> (1)</linkHtml>
                           <br/>â¢ To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) â¥2 mg/L, and at least one additional CV risk factor.<br/>â¢ As an adjunct to diet to:<br/>Âº reduce LDL-C in adults with primary hyperlipidemia.<br/>ÂºÂ reduce LDL-C and slow the progression of atherosclerosis in adults.<br/>Âº reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).<br/>â¢ As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).<br/>â¢ As an adjunct to diet for the treatment of adults with:<br/>ÂºÂ Primary dysbetalipoproteinemia.<br/>ÂºÂ Hypertriglyceridemia.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_c0650ff0-6f19-4b9a-be5a-0db2e0d6804a">
               <id root="4f86c96f-b791-4369-8aad-a4f2340df73b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Take orally with or without food, at any time of day. (<linkHtml href="#ID_297c18c5-1dc3-4aed-a926-c2432b312de6">2.1</linkHtml>)</paragraph>
                        <paragraph>Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ROSUVASTATIN TABLETS, and adjust dosage if necessary. (<linkHtml href="#ID_297c18c5-1dc3-4aed-a926-c2432b312de6">2.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Adults:</content> Recommended dosage range is 5 to 40 mg once daily. (<linkHtml href="#ID_297c18c5-1dc3-4aed-a926-c2432b312de6">2.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients with HeFH:</content> Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. (<linkHtml href="#ID_b5d43916-4d4c-4a64-8d70-61a4eecb7caa">2.2</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients with HoFH:</content> Recommended dosage is 20 mg once daily for patients aged 7 years and older. (<linkHtml href="#ID_b5d43916-4d4c-4a64-8d70-61a4eecb7caa">2.2</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Asian Patients:</content> Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. (<linkHtml href="#ID_3f8a0510-38d1-4e61-9eff-e8bc8324913a">2.4</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Severe Renal Impairment (not on hemodialysis):</content> Initiate at 5 mg once daily; do not exceed 10 mg once daily. (<linkHtml href="#ID_b5a01c17-299c-44aa-8504-5ec5628ca1f4">2.5</linkHtml>)</paragraph>
                        <paragraph>See full prescribing information forÂ ROSUVASTATIN TABLETS dosage and administration modifications due to drug interactions. (<linkHtml href="#ID_f954dfd4-4729-4787-ba58-79814a4fa6a8">2.6</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_297c18c5-1dc3-4aed-a926-c2432b312de6">
                     <id root="88fe3e92-cd6d-44e7-9a55-adceeaaafa1b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 General Dosage and Administration Information</title>
                     <text>
                        <paragraph>â¢ AdministerÂ rosuvastatin tablets orally as a single dose at any time of day, with or without food. Swallow the tablets whole.</paragraph>
                        <paragraph>â¢ Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin tablets, and adjust the dosage if necessary.</paragraph>
                        <paragraph>â¢ If a dose is missed, advise patients not to take an extra dose. Resume treatment with the next dose.</paragraph>
                        <paragraph>â¢ When takingÂ rosuvastatin tablets with an aluminum and magnesium hydroxide combination antacid, administerÂ rosuvastatin tablets at least 2 hours before the antacid <content styleCode="italics">[see <linkHtml href="#ID_87add7e4-e73b-4d14-b5f6-77a36662e2d1">Drug Interactions (7.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b5d43916-4d4c-4a64-8d70-61a4eecb7caa">
                     <id root="700e5790-5636-4579-9c63-fa347f42233e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage in Adult Patients</title>
                     <text>
                        <paragraph>â¢ The dosage range forÂ rosuvastatin tablets is 5 to 40 mg orally once daily.</paragraph>
                        <paragraph>â¢ The recommended dose ofÂ rosuvastatin tablets depends on a patientâs indication for usage, LDL-C, and individual risk for CV events.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_dba1df19-5276-40de-80d9-4522320bc924">
                     <id root="4251bcbc-3b31-443e-9d22-8183ea191120"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Dosage in Pediatric Patients</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Dosage in Pediatric Patients 8 Years of Age and Older with HeFH</content>
                        </paragraph>
                        <paragraph>The recommended dosage range is 5 mg to 10 mg orally once daily in patients aged 8 years to less than 10Â years and 5 mg to 20 mg orally once daily in patients aged 10 years and older.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dosage in Pediatric Patients 7 Years of Age and Older with HoFH</content>
                        </paragraph>
                        <paragraph>The recommended dosage is 20 mg orally once daily.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3f8a0510-38d1-4e61-9eff-e8bc8324913a">
                     <id root="68e3c75e-82aa-4c70-9c24-790aef33dba7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosing in Asian Patients</title>
                     <text>
                        <paragraph>InitiateÂ rosuvastatin tablets at 5 mg once daily due to increased rosuvastatin plasma concentrations. Consider the risks and benefits ofÂ rosuvastatin tablets when treating Asian patients not adequately controlled at doses up to 20 mg once <content styleCode="italics">daily [see <linkHtml href="#ID_149e50ef-0d0b-4f40-b1c3-d8b38843366a">Warnings and Precautions (5.1)</linkHtml>, <linkHtml href="#ID_8f018e35-3ee2-4090-a9c6-997d4f8c76a6">Use in Specific Populations (8.8)</linkHtml>, and <linkHtml href="#ID_c0ada22f-7299-4bd7-a1d9-1134fd2612ff">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b5a01c17-299c-44aa-8504-5ec5628ca1f4">
                     <id root="98c21201-a036-4c79-8275-e8cd009fd56a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Recommended Dosage in Patients with Renal Impairment</title>
                     <text>
                        <paragraph>In patients with severe renal impairment (CL<sub>cr</sub> less than 30 mL/min/1.73 m<sup>2</sup>) not on hemodialysis, the recommended starting dosage is 5 mg once daily and should not exceed 10 mg once daily <content styleCode="italics">[see <linkHtml href="#ID_149e50ef-0d0b-4f40-b1c3-d8b38843366a">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#ID_a3054989-2947-4434-9202-7cac8b00d71f">Use in Specific Populations (8.6)</linkHtml>]</content>.</paragraph>
                        <paragraph>There are no dosage adjustment recommendations for patients with mild and moderate renal impairment.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f954dfd4-4729-4787-ba58-79814a4fa6a8">
                     <id root="46164bd0-e129-4357-ba11-a388b1bfd09a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage Modifications Due to Drug Interactions </title>
                     <text>
                        <paragraph>Table 1 displays dosage modifications forÂ rosuvastatin tablets due to drug interactions <content styleCode="italics">[see <linkHtml href="#ID_149e50ef-0d0b-4f40-b1c3-d8b38843366a">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#ID_b68001d0-9698-48d8-a06d-15a265894e79">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                        <table ID="_RefID0EYAAG" width="100%">
                           <caption>Table 1:Â Â Â Â Rosuvastatin Tablets Dosage Modifications Due to Drug Interactions</caption>
                           <colgroup>
                              <col width="59%"/>
                              <col width="41%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Concomitantly Used Drug</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Rosuvastatin TabletsDosage Modifications </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Cyclosporine</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Do not exceed 5 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Teriflunomide</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Do not exceed 10 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Enasidenib</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Do not exceed 10 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Capmatinib</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Do not exceed 10 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Fostamatinib</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Do not exceed 20 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Febuxostat</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Do not exceed 20 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Gemfibrozil</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Avoid concomitant use. If used concomitantly, initiate at 5 mg once daily and do not exceed 10 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Tafamidis</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Avoid concomitant use. If used concomitantly, initiate at 5 mg once daily and do not exceed 20 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="top">
                                    <paragraph>Antiviral Medications</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Â  â¢Sofbuvir/velpatasvir/voxilaprevir</paragraph>
                                    <paragraph>Â  â¢Ledipasvir/sofosbuvir</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Concomitant use not recommended.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Â  â¢Simeprevir</paragraph>
                                    <paragraph>Â  â¢Dasabuvir/ombitasvir/paritaprevir/ritonavir</paragraph>
                                    <paragraph>Â  â¢Elbasvir/Grazoprevir</paragraph>
                                    <paragraph>Â  â¢Sofosbuvir/Velpatasvir</paragraph>
                                    <paragraph>Â  â¢Glecaprevir/Pibrentasvir</paragraph>
                                    <paragraph>Â  â¢Atazanavir/Ritonavir</paragraph>
                                    <paragraph>Â  â¢Lopinavir/Ritonavir</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Initiate at 5 mg once daily. Do not exceed 10 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Darolutamide</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Do not exceed 5 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Regorafenib</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Do not exceed 10 mg once daily.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_af0a2ff1-ba64-4bfe-b438-81a396c491b4">
               <id root="fa77b041-53f6-4eed-b14e-fde482719e08"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>Rosuvastatin tablets:</paragraph>
                  <paragraph>â¢Â  5 mg: Round, yellow film coated tablet, biconvex, one side of the tablet debossed âY16â, the other side is smooth.</paragraph>
                  <paragraph>â¢ 10 mg: Round, pink film coated tablet, biconvex, one side of the tablet debossed âY17â, the other side is smooth.</paragraph>
                  <paragraph>â¢ 20 mg: Round, yellow film coated tablet, biconvex, one side of the tablet debossed âY19â, the other side is smooth.</paragraph>
                  <paragraph>â¢ 40 mg: Round, pink film coated tablet, biconvex, one side of the tablet debossed âY20â, the other side is smooth.</paragraph>
               </text>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 5 mg, 10 mg, 20 mg, and 40 mg of rosuvastatin. (<linkHtml href="#ID_af0a2ff1-ba64-4bfe-b438-81a396c491b4">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_07d6d429-7e43-49f5-b63b-60ffc7e72566">
               <id root="0821ba3a-d124-496b-990b-0ac1ea6b6a85"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>Rosuvastatin tablets are contraindicated in the following conditions:</paragraph>
                  <paragraph>â¢ Acute liver failure or decompensated cirrhosis <content styleCode="italics">[see <linkHtml href="#ID_2d070474-0c2b-41ba-a0a0-2d01988bdddf">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                  <paragraph>â¢Hypersensitivity to rosuvastatin or any excipients in rosuvastatin tablets. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported withÂ rosuvastatin tabletsÂ <content styleCode="italics">[see <linkHtml href="#ID_f810a7d4-640d-42d8-9be5-bad9a6420a0b">Adverse Reactions (6.1)</linkHtml>]</content>.</paragraph>
               </text>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Acute liver failure or decompensated cirrhosis. (<linkHtml href="#ID_07d6d429-7e43-49f5-b63b-60ffc7e72566">4</linkHtml>)</paragraph>
                        <paragraph>Hypersensitivity to rosuvastatin or any excipients in ROSUVASTATIN TABLETS. (<linkHtml href="#ID_07d6d429-7e43-49f5-b63b-60ffc7e72566">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_8feb70a7-5e35-44a2-bf85-1b10b3e7ebe8">
               <id root="7d060ff9-91b0-4a1f-a6f9-72e09d8fee99"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>â¢<content styleCode="italics">Myopathy and Rhabdomyolysis</content>: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higherÂ ROSUVASTATIN TABLETS dosage. Asian patients may be at higher risk for myopathy. DiscontinueÂ ROSUVASTATIN TABLETS if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinueÂ ROSUVASTATIN TABLETS in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasingÂ ROSUVASTATIN TABLETS dosage. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. (<linkHtml href="#ID_149e50ef-0d0b-4f40-b1c3-d8b38843366a">5.1</linkHtml>)</paragraph>
                        <paragraph>â¢<content styleCode="italics">Immune-Mediated Necrotizing Myopathy (IMNM)</content>: Rare reports of IMNM, an autoimmune myopathy, have been reported with statin use. DiscontinueÂ ROSUVASTATIN TABLETS if IMNM is suspected. (<linkHtml href="#ID_d836799b-03a9-49af-a753-7683b406deec">5.2</linkHtml>)</paragraph>
                        <paragraph>â¢<content styleCode="italics">Hepatic Dysfunction</content>: Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzymes before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue ROSUVASTATIN TABLETS. (<linkHtml href="#ID_2d070474-0c2b-41ba-a0a0-2d01988bdddf">5.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_149e50ef-0d0b-4f40-b1c3-d8b38843366a">
                     <id root="7cb54bc1-8055-46e6-8153-8feba7ae4bbe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Myopathy and Rhabdomyolysis</title>
                     <text>
                        <paragraph>Rosuvastatin tabletsÂ may cause myopathy [muscle pain, tenderness, or weakness associated with elevated creatine kinase (CK)] and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis with statins, including rosuvastatin tablets.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Factors for Myopathy</content>
                        </paragraph>
                        <paragraph>Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higherÂ rosuvastatin tablets dosage. Asian patients on rosuvastatin tablets may be at higher risk for myopathy <content styleCode="italics">[see <linkHtml href="#ID_b68001d0-9698-48d8-a06d-15a265894e79">Drug Interactions (7.1)</linkHtml> and <linkHtml href="#ID_8f018e35-3ee2-4090-a9c6-997d4f8c76a6">Use in Specific Populations (8.8)</linkHtml>]</content>. The myopathy risk is greater in patients takingÂ rosuvastatin tablets 40 mg daily compared with lowerÂ rosuvastatin tablets dosages.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis</content>
                        </paragraph>
                        <paragraph>The concomitant use ofÂ rosuvastatin tablets with cyclosporine or gemfibrozil is not recommended.Â Rosuvastatin tablets dosage modifications are recommended for patients taking certain antiviral medications, darolutamide, and regorafenib <content styleCode="italics">[see <linkHtml href="#ID_f954dfd4-4729-4787-ba58-79814a4fa6a8">Dosage and Administration (2.6)</linkHtml>]</content>. Niacin, fibrates, and colchicine may also increase the risk of myopathy and rhabdomyolysis <content styleCode="italics">[see <linkHtml href="#ID_b68001d0-9698-48d8-a06d-15a265894e79">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                        <paragraph>Discontinue rosuvastatin tablets if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK elevations may resolve ifÂ rosuvastatin tablets is discontinued. Temporarily discontinueÂ rosuvastatin tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis (e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy).</paragraph>
                        <paragraph>Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing theÂ rosuvastatin tablets dosage. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d836799b-03a9-49af-a753-7683b406deec">
                     <id root="881a6bba-1e3b-441c-b6a8-9964e0c7c0ec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Immune-Mediated Necrotizing Myopathy </title>
                     <text>
                        <paragraph>There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or a different statin was administered. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. DiscontinueÂ rosuvastatin tablets if IMNM is suspected.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2d070474-0c2b-41ba-a0a0-2d01988bdddf">
                     <id root="83cc985f-17d1-4389-b105-94b8141f715a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hepatic Dysfunction</title>
                     <text>
                        <paragraph>Increases in serum transaminases have been reported with use ofÂ rosuvastatin tabletsÂ <content styleCode="italics">[see <linkHtml href="#ID_f810a7d4-640d-42d8-9be5-bad9a6420a0b">Adverse Reactions (6.1)</linkHtml>]</content>. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy. In a pooled analysis of placebo-controlled trials, increases in serum transaminases to more than three times the ULN occurred in 1.1% of patients takingÂ rosuvastatin tablets versus 0.5% of patients treated with placebo. Marked persistent increases of hepatic transaminases have also occurred with rosuvastatin tablets. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including rosuvastatin tablets.</paragraph>
                        <paragraph>Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury <content styleCode="italics">[see <linkHtml href="#ID_6f2a4150-06d9-4238-8e34-0870057073e7">Use in Specific Populations (8.7)</linkHtml>]</content>.</paragraph>
                        <paragraph>Consider liver enzyme testing beforeÂ rosuvastatin tablets initiation and when clinically indicated thereafter.Â Rosuvastatin tablets is contraindicated in patients with acute liver failure or decompensated cirrhosis <content styleCode="italics">[see <linkHtml href="#ID_07d6d429-7e43-49f5-b63b-60ffc7e72566">Contraindications (4)</linkHtml>]</content>. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue rosuvastatin tablets.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e18654e7-9cf4-4d87-952c-345d85677f40">
                     <id root="b1af8b80-3aad-4d73-afde-c1736d8e3a8f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Proteinuria and Hematuria</title>
                     <text>
                        <paragraph>In theÂ rosuvastatin tablets clinical trial program, dipstick-positive proteinuria and microscopic hematuria were observed amongÂ rosuvastatin tablets treated patients. These findings were more frequent in patients takingÂ rosuvastatin tablets 40 mg, when compared to lower doses of rosuvastatin tablets or comparator statins, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, consider a dose reduction for patients onÂ rosuvastatin tablets therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_d2f4af30-908e-4f9f-9477-fcc323906901">
                     <id root="196268b6-2f4b-4ae7-99cd-2594021a2a34"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Increases in HbA1c and Fasting Serum Glucose Levels</title>
                     <text>
                        <paragraph>Increases in HbA1c and fasting serum glucose levels have been reported with statins, including rosuvastatin tablets. Based on clinical trial data with rosuvastatin tablets, in some instances these increases may exceed the threshold for the diagnosis of diabetes mellitus <content styleCode="italics">[see <linkHtml href="#ID_f810a7d4-640d-42d8-9be5-bad9a6420a0b">Adverse Reactions (6.1)</linkHtml>]</content>. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_51f6c33d-ff5c-4ea1-b521-74288beec651">
               <id root="f3f64350-fcf4-42a6-a987-33edc67d6ee0"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following important adverse reactions are described below and elsewhere in the labeling:</paragraph>
                  <paragraph>Myopathy and Rhabdomyolysis <content styleCode="italics">[see <linkHtml href="#ID_149e50ef-0d0b-4f40-b1c3-d8b38843366a">Warnings and Precautions (5.1)</linkHtml>]</content>
                  </paragraph>
                  <paragraph>Immune-Mediated Necrotizing Myopathy <content styleCode="italics">[see <linkHtml href="#ID_d836799b-03a9-49af-a753-7683b406deec">Warnings and Precautions (5.2)</linkHtml>]</content>
                  </paragraph>
                  <paragraph>Hepatic Dysfunction <content styleCode="italics">[see <linkHtml href="#ID_2d070474-0c2b-41ba-a0a0-2d01988bdddf">Warnings and Precautions (5.3)</linkHtml>]</content>
                  </paragraph>
                  <paragraph>Proteinuria and Hematuria <content styleCode="italics">[see <linkHtml href="#ID_e18654e7-9cf4-4d87-952c-345d85677f40">Warnings and Precautions (5.4)</linkHtml>]</content>
                  </paragraph>
                  <paragraph>Increases in HbA1c and Fasting Serum Glucose Levels <content styleCode="italics">[see <linkHtml href="#ID_d2f4af30-908e-4f9f-9477-fcc323906901">Warnings and Precautions (5.5)</linkHtml>]</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most frequent adverse reactions (rate â¥2%) are headache, nausea, myalgia, asthenia, and constipation. (<linkHtml href="#ID_f810a7d4-640d-42d8-9be5-bad9a6420a0b">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contactÂ 1-888-900-1006 or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_f810a7d4-640d-42d8-9be5-bad9a6420a0b">
                     <id root="9b2d571b-0477-46b8-ba57-a2b69ccc4221"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>Adverse reactions reported in â¥2% of patients in placebo-controlled clinical studies and at a rate greater than placebo are shown in Table 2. These studies had a treatment duration of up to 12 weeks.</paragraph>
                        <table ID="_RefID0ETSAG" width="100%">
                           <caption>Table 2: Adverse Reactions Reported in â¥2% of Patients Treated withÂ Rosuvastatin Tablets and &gt; Placebo in Placebo-Controlled Trials</caption>
                           <colgroup>
                              <col width="18%"/>
                              <col width="12%"/>
                              <col width="13%"/>
                              <col width="13%"/>
                              <col width="13%"/>
                              <col width="13%"/>
                              <col width="18%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reactions</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=382</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Rosuvastatin tablets</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">5Â mg</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=291</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Rosuvastatin tablets</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">10Â mg</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=283</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Rosuvastatin tablets</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">20Â mg</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=64</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Rosuvastatin tablets</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">40Â mg</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=106</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Total</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Rosuvastatin tablets</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">5Â mg</content>â<content styleCode="bold">40Â mg</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=744</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>5.0</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>5.5</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>4.9</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>3.1</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>8.5</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>5.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>3.1</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>3.8</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>3.5</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>6.3</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>3.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Myalgia</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>1.3</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>3.1</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.1</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>6.3</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>1.9</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Asthenia</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.6</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.4</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>3.2</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>4.7</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>0.9</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Constipation</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.4</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.1</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.1</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>4.7</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.8</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.4</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Other adverse reactions reported in clinical studies were abdominal pain, dizziness, hypersensitivity (including rash, pruritus, urticaria, and angioedema) and pancreatitis. The following laboratory abnormalities have also been reported: dipstick-positive proteinuria and microscopic hematuria; elevated creatine phosphokinase, transaminases, glucose, glutamyl transpeptidase, alkaline phosphatase, and bilirubin; and thyroid function abnormalities.</paragraph>
                        <paragraph>In the METEOR study, patients were treated withÂ rosuvastatin 40 mg (n=700) or placebo (n=281) with a mean treatment duration of 1.7 years. Adverse reactions reported in â¥2% of patients and at a rate greater than placebo are shown in TableÂ 3.</paragraph>
                        <table ID="_RefID0EA3AG" width="100%">
                           <caption>Table 3: Adverse Reactions Reported in â¥2% of Patients Treated with Rosuvastatin Tablets and &gt; Placebo in the METEOR Trial</caption>
                           <colgroup>
                              <col width="35%"/>
                              <col width="32%"/>
                              <col width="34%"/>
                           </colgroup>
                           <thead>
                              <tr styleCode="First Last">
                                 <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                                    <content styleCode="bold">Adverse Reactions</content>
                                 </th>
                                 <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <content styleCode="bold">Placebo </content>
                                    <br/>
                                    <content styleCode="bold">N=281</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </th>
                                 <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <content styleCode="bold">Rosuvastatin tabletsÂ 40Â mg </content>
                                    <br/>
                                    <content styleCode="bold">N=700</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>Myalgia</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>12.1</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>12.7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Arthralgia</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>7.1</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>10.1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>5.3</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>6.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Dizziness</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.8</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>4.0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Increased CPK</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>0.7</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Abdominal pain</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>1.8</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>ALT greater than 3x ULN<footnote ID="_Ref119584964">Frequency recorded as abnormal laboratory value.</footnote>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>0.7</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.2</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In the JUPITER study, patients were treated withÂ rosuvastatin 20 mg (n=8,901) or placebo (n=8,901) for a mean duration of 2 years. In JUPITER, there was a significantly higher frequency of diabetes mellitus reported in patients taking rosuvastatin (2.8%) versus patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in rosuvastatin-treated patients compared to placebo-treated patients. The number of patients with a HbA1c &gt;6.5% at the end of the trial was significantly higher in rosuvastatin-treated versus placebo-treated patients <content styleCode="italics">[see <linkHtml href="#ID_87f36f0e-09d0-4356-8575-7cd6a0114a6a">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                        <paragraph>Adverse reactions reported in â¥2% of patients and at a rate greater than placebo are shown in Table 4.</paragraph>
                        <table ID="_RefID0EABBG" width="100%">
                           <caption>Table 4: Adverse Reactions Reported in â¥2% of Patients Treated withÂ Rosuvastatin Tablets and &gt; Placebo in the JUPITER Trial</caption>
                           <colgroup>
                              <col width="35%"/>
                              <col width="31%"/>
                              <col width="33%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reactions</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Placebo</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=8ï¼901</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Rosuvastatin tabletsÂ 20Â mg</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">N=8ï¼901</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Myalgia</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>6.6</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>7.6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Arthralgia</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>3.2</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>3.8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Constipation</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>3.0</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>3.3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Diabetes mellitus</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.3</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.3</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>2.4</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients with HeFH</content>
                        </paragraph>
                        <paragraph>In a 12âweek controlled study in pediatric patients 10 to 17 years of age with HeFH withÂ rosuvastatin 5 mg to 20 mg daily <content styleCode="italics">[see <linkHtml href="#ID_c91fae6d-6692-43ae-a53f-011ecc5c7d21">Use in Specific Populations (8.4)</linkHtml> and <linkHtml href="#ID_87f36f0e-09d0-4356-8575-7cd6a0114a6a">Clinical Studies (14)</linkHtml>]</content>, elevations in serum CK greater than 10Â x ULN were observed more frequently in rosuvastatin-treated patients compared with patients receiving placebo. Four of 130 (3%) patients treated withÂ rosuvastatin (2 treated with 10 mg and 2 treated with 20 mg) had increased CK greater than 10 x ULN, compared to 0 of 46 patients on placebo.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_09512bbe-2aa4-4027-842a-f70fc85ef7f4">
                     <id root="11d50aeb-f7d0-40b6-a85c-975efc522a42"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of rosuvastatin tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Blood Disorders</content>: thrombocytopenia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatobiliary Disorders</content>: hepatitis, jaundice, fatal and non-fatal hepatic failure</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal Disorders</content>: arthralgia, rare reports of immune-mediated necrotizing myopathy associated with statin use</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous System Disorders</content>: peripheral neuropathy, rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, and confusion) associated with the use of all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks). There have been rare reports of new-onset or exacerbation of myasthenia gravis, including ocular myasthenia, and reports of recurrence when the same or a different statin was administered.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric Disorders</content>: depression, sleep disorders (including insomnia and nightmares)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Reproductive System and Breast Disorders</content>: gynecomastia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory Disorders</content>: interstitial lung disease</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and Subcutaneous Tissue Disorders</content>: drug reaction with eosinophilia and systemic symptoms (DRESS), lichenoid drug eruption</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_ce018325-6b6e-4c52-a9cc-3fb0eeff1ecb">
               <id root="730733f7-4755-4bdc-8524-9562ccef341b"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>See full prescribing information for details regarding concomitant use ofÂ ROSUVASTATIN TABLETS with other drugs that increase the risk of myopathy and rhabdomyolysis. (<linkHtml href="#ID_b68001d0-9698-48d8-a06d-15a265894e79">7.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Aluminum and Magnesium Hydroxide Combination Antacids</content>: AdministerÂ ROSUVASTATIN TABLETS at least 2 hours before the antacid. ( <linkHtml href="#ID_87add7e4-e73b-4d14-b5f6-77a36662e2d1">7.2</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Wafarin</content>: Obtain INR prior to starting ROSUVASTATIN TABLETS. Monitor INR frequently until stable upon initiation, dose titration or discontinuation. (<linkHtml href="#ID_243c2e29-7c8e-488b-a4f7-fd0ca69571ff">7.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_b68001d0-9698-48d8-a06d-15a265894e79">
                     <id root="d9681951-a21b-4311-a1b8-65a5d6f2a468"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Rosuvastatin Tablets</title>
                     <text>
                        <paragraph>Rosuvastatin is a substrate of CYP2C9 and transporters (such as OATP1B1, BCRP). Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. Table 5 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when used concomitantly with rosuvastatin tablets and instructions for preventing or managing them <content styleCode="italics">[see <linkHtml href="#ID_149e50ef-0d0b-4f40-b1c3-d8b38843366a">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#ID_c0ada22f-7299-4bd7-a1d9-1134fd2612ff">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <table ID="_RefID0EWIBG" width="100%">
                           <caption>Table 5: Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis withÂ Rosuvastatin Tablets</caption>
                           <colgroup>
                              <col width="26%"/>
                              <col width="54%"/>
                              <col width="20%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Cyclosporine</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Cyclosporine increased rosuvastatin exposure 7-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine or gemfibrozil with rosuvastatin tablets.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>If used concomitantly, do not exceed a dose ofÂ rosuvastatin tablets 5 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Teriflunomide</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Teriflunomide increased rosuvastatin exposure more than 2.5-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>In patients taking teriflunomide, do not exceed a dose ofÂ rosuvastatin tablets 10 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Enasidenib</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="top">
                                    <paragraph>Enasidenib increased rosuvastatin exposure more than 2.4-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="top">
                                    <paragraph>In patients taking enasidenib, do not exceed a dose ofÂ rosuvastatin tablets 10 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Capmatinib</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Capmatinib increased rosuvastatin exposure more than 2.1-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>In patients taking capmatinib, do not exceed a dose of rosuvastatin tablets 10 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Fostamatinib</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Fostamatinib increased rosuvastatin exposure more than 2.0-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>In patients taking fostamatinib, do not exceed a dose ofÂ rosuvastatin tablets 20 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Febuxostat</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Febuxostat increased rosuvastatin exposure more than 1.9-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>In patients taking febuxostat, do not exceed a dose ofÂ rosuvastatin tablets 20 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Gemfibrozil</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Gemfibrozil significantly increased rosuvastatin exposure and gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of gemfibrozil with rosuvastatin tablets.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Avoid concomitant use of gemfibrozil with rosuvastatin tablets. If used concomitantly, initiateÂ rosuvastatin tablets at 5 mg once daily and do not exceed a dose ofÂ rosuvastatin tablets 10 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Tafamidis</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Tafamidis significantly increased rosuvastatin exposure and tafamidis may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of tafamidis with rosuvastatin tablets.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention: </content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Avoid concomitant use of tafamidis with rosuvastatin tablets. If used concomitantly, initiateÂ rosuvastatin tablets at 5 mg once daily and do not exceed a dose ofÂ rosuvastatin tablets 20 mg once daily. Monitor for signs of myopathy and rhabdomyolysis if used concomitantly with rosuvastatin tablets.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Anti-Viral Medications</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Rosuvastatin plasma levels were significantly increased with concomitant administration of many anti-viral drugs, which increases the risk of myopathy and rhabdomyolysis.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="middle">
                                    <paragraph>â¢Sofosbuvir/velpatasvir/voxilaprevir</paragraph>
                                    <paragraph>â¢Ledipasvir/sofosbuvir</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Avoid concomitant use with rosuvastatin tablets.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="middle"/>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>â¢Simeprevir</paragraph>
                                    <paragraph>â¢Dasabuvir/ombitasvir/paritaprevir/ritonavir</paragraph>
                                    <paragraph>â¢Elbasvir/grazoprevir</paragraph>
                                    <paragraph>â¢Sofosbuvir/velpatasvir</paragraph>
                                    <paragraph>â¢Glecaprevir/pibrentasvir</paragraph>
                                    <paragraph>â¢Atazanavir/ritonavir</paragraph>
                                    <paragraph>â¢Lopinavir/ritonavir</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="middle">
                                    <paragraph>Initiate withÂ rosuvastatin tablets 5 mg once daily, and do not exceed a dose ofÂ rosuvastatin tablets 10 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Darolutamide</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>Clinical Impact:</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Darolutamide increased rosuvastatin exposure more than 5-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>Intervention:</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>In patients taking darolutamide, do not exceed a dose ofÂ rosuvastatin tablets 5 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Regorafenib </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Regorafenib increased rosuvastatin exposure and may increase the risk of myopathy.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>In patients taking regorafenib, do not exceed a dose ofÂ rosuvastatin tablets 10 mg once daily.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Fenofibrates (e.g., fenofibrate and fenofibric acid)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with rosuvastatin tablets.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Consider if the benefit of using fibrates concomitantly withÂ rosuvastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Niacin</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Cases of myopathy and rhabdomyolysis have occurred with concomitant use of lipid-modifying doses (â¥1Â g/day) of niacin with rosuvastatin tablets.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Consider if the benefit of using lipid-modifying doses (â¥1Â g/day) of niacin concomitantly withÂ rosuvastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Colchicine</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with rosuvastatin tablets.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" colspan="2" valign="middle">
                                    <paragraph>Consider if the benefit of using colchicine concomitantly withÂ rosuvastatin tablets outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="3" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Ticagrelor</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" valign="middle">
                                    <paragraph>Concomitant use ofÂ rosuvastatin tablets and ticagrelor has been shown to increase rosuvastatin concentrations, which may result in increased risk of myopathy. Cases of myopathy and rhabdomyolysis have been reported in patients using both products concomitantly. Cases have occurred more frequently in patients taking 40 mg of rosuvastatin.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" valign="middle">
                                    <paragraph>In patients taking concomitant ticagrelor, especially those with additional risk factors for myopathy and rhabdomyolysis, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of rosuvastatin tablets.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_87add7e4-e73b-4d14-b5f6-77a36662e2d1">
                     <id root="41e6ab16-dca9-4e8f-b423-6102988dcea4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Drug Interactions that Decrease the Efficacy ofÂ Rsuvastatin Tablets</title>
                     <text>
                        <paragraph>Table 6 presents drug interactions that may decrease the efficacy ofÂ rosuvastatin tablets and instructions for preventing or managing them.</paragraph>
                        <table ID="_RefID0ESZBG" width="100%">
                           <caption>Table 6: Drug Interactions that Decrease the Efficacy ofÂ Rsuvastatin Tablets</caption>
                           <colgroup>
                              <col width="21%"/>
                              <col width="79%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Antacids</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="middle">
                                    <paragraph>Concomitant aluminum and magnesium hydroxide combination antacid administration decreased the mean exposure of rosuvastatin 50% <content styleCode="italics">[see <linkHtml href="#ID_c0ada22f-7299-4bd7-a1d9-1134fd2612ff">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="middle">
                                    <paragraph>In patients taking antacid, administer rosuvastatin tabletsat least 2 hours before the antacid.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_243c2e29-7c8e-488b-a4f7-fd0ca69571ff">
                     <id root="7f676a09-842d-4614-8cd8-ebd0168d499e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3Â Rsuvastatin Tablets Effects on Other Drugs</title>
                     <text>
                        <paragraph>Table 7 presents rsuvastatin tabletsâ effect on other drugs and instructions for preventing or managing them.</paragraph>
                        <table ID="_RefID0EQ2BG" width="100%">
                           <caption>Table 7:Â Rsuvastatin Tablets Effects on Other Drugs</caption>
                           <colgroup>
                              <col width="21%"/>
                              <col width="79%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" colspan="2" valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Warfarin</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="middle">
                                    <paragraph>Rosuvastatin significantly increased the INR in patients receiving warfarin <content styleCode="italics">[see <linkHtml href="#ID_c0ada22f-7299-4bd7-a1d9-1134fd2612ff">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="middle">
                                    <paragraph>In patients taking warfarin, obtain an INR before startingÂ rosuvastatin tablets and frequently enough after initiation, dose titration or discontinuation to ensure that no significant alteration in INR occurs. Once the INR is stable, monitor INR at regularly recommended intervals.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250228"/>
                     <component>
                        <section ID="Le977c0c0-f21d-4da1-9f5f-c94ab69cbb67">
                           <id root="fe46f01a-0a64-4350-bccc-261b76b46008"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title/>
                           <text/>
                           <effectiveTime value="20250228"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_eb85edb9-3418-4cbb-8d8e-c2e70707fb61">
               <id root="a8e6d038-c467-451d-bef3-4f579e12fb8e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20250228"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>â¢<content styleCode="italics">Pregnancy</content>: May cause fetal harm. (<linkHtml href="#ID_c80a1e31-4f4c-4332-8d44-f96b9258cb21">8.1</linkHtml>)</paragraph>
                        <paragraph>â¢<content styleCode="italics">Lactation</content>: Breastfeeding not recommended during treatment with ROSUVASTATIN TABLETS. (<linkHtml href="#ID_aec55442-b0d6-4ac8-99ff-80041069c027">8.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_c80a1e31-4f4c-4332-8d44-f96b9258cb21">
                     <id root="9bb331d5-232f-43d6-95e7-b27e60f0e139"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>DiscontinueÂ rosuvastatin tablets when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient.</paragraph>
                        <paragraph>Rosuvastatin tabletsÂ decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, rosuvastatin tablets may cause fetal harm when administered to pregnant patients based on the mechanism of action<content styleCode="italics"> [see <linkHtml href="#ID_fd674746-d0e7-4e46-8245-532d76fdb8f0">Clinical Pharmacology (12.1)</linkHtml>]</content>. In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients.</paragraph>
                        <paragraph>Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations. Published data from prospective and retrospective observational cohort studies withÂ rosuvastatin tablets use in pregnant women are insufficient to determine if there is a drug-associated risk of miscarriage <content styleCode="italics">(see Data)</content>.</paragraph>
                        <paragraph>In animal reproduction studies, no adverse developmental effects were observed in pregnant rats or rabbits orally administered rosuvastatin during the period of organogenesis at doses that resulted in systemic exposures equivalent to human exposures at the maximum recommended human dose (MRHD) of 40 mg/day, based on AUC and body surface area (mg/m<sup>2</sup>), respectively <content styleCode="italics">(see Data)</content>.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>A Medicaid cohort linkage study of 1,152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders â including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use â using propensity score-based methods. The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>In female rats given 5, 15 and 50 mg/kg/day before mating and continuing through to gestation day 7 resulted in decreased fetal body weight (female pups) and delayed ossification at 50 mg/kg/day (10 times the human exposure at the MRHD dose of 40 mg/day based on AUC).</paragraph>
                        <paragraph>In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day 7 through lactation day 21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to 12 times the MRHD of 40 mg/day based body surface area).</paragraph>
                        <paragraph>In pregnant rabbits given 0.3, 1, and 3 mg/kg/day of rosuvastatin from gestation day 6 to day 18, decreased fetal viability and maternal mortality was observed at 3 mg/kg/day (dose equivalent to the MRHD of 40 mg/day based on body surface area).</paragraph>
                        <paragraph>Rosuvastatin crosses the placenta in rats and rabbits and is found in fetal tissue and amniotic fluid at 3% and 20%, respectively, of the maternal plasma concentration following a single 25 mg/kg oral gavage dose on gestation day 16 in rats. In rabbits, fetal tissue distribution was 25% of maternal plasma concentration after a single oral gavage dose of 1 mg/kg on gestation day 18.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_aec55442-b0d6-4ac8-99ff-80041069c027">
                     <id root="fd5877d7-01d8-4322-b1cf-32a159a2c95a"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Limited data from case reports in published literature indicate thatÂ rosuvastatin tablets are present in human milk. There is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. Statins, including rosuvastatin tablets, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant.</paragraph>
                        <paragraph>Because of the potential for serious adverse reactions in a breastfed infant, based on the mechanism of action, advise patients that breastfeeding is not recommended during treatment withÂ rosuvastatin tabletsÂ <content styleCode="italics">[see <linkHtml href="#ID_c80a1e31-4f4c-4332-8d44-f96b9258cb21">Use in Specific Populations (8.1)</linkHtml> and <linkHtml href="#ID_fd674746-d0e7-4e46-8245-532d76fdb8f0">Clinical Pharmacology (12.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c91fae6d-6692-43ae-a53f-011ecc5c7d21">
                     <id root="7632c973-5fde-44b3-bc3e-02ca71dee873"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness ofÂ rosuvastatin tablets as an adjunct to diet to reduce LDL-C have been established in pediatric patients 8 years of age and older with HeFH. Use ofÂ rosuvastatin tablets for this indication is based on one 12-week controlled trial with a 40-week open-label extension period in 176 pediatric patients 10 years of age and older with HeFH and one 2âyear open-label, uncontrolled trial in 175 pediatric patients 8 years of age and older with HeFH <content styleCode="italics">[see <linkHtml href="#ID_87f36f0e-09d0-4356-8575-7cd6a0114a6a">Clinical Studies (14)</linkHtml>]</content>. In the 1-year trial with a 12-week controlled phase, there was no detectable effect ofÂ rosuvastatin tablets on growth, weight, BMI (body mass index), or sexual maturation in patients aged 10 to 17 years.</paragraph>
                        <paragraph>The safety and effectiveness ofÂ rosuvastatin tablets as an adjunct to other LDL-C-lowering therapies to reduce LDL-C have been established in pediatric patients 7 years of age and older with HoFH. Use of rosuvastatin tablets for this indication is based on a randomized, placebo-controlled, cross-over study in 14 pediatric patients 7 years of age and older with HoFH <content styleCode="italics">[see <linkHtml href="#ID_87f36f0e-09d0-4356-8575-7cd6a0114a6a">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                        <paragraph>The safety and effectiveness ofÂ rosuvastatin tablets have not been established in pediatric patients younger than 8 years of age with HeFH, younger than 7 years of age with HoFH, or in pediatric patients with other types of hyperlipidemia (other than HeFH or HoFH).</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2822c9ec-2a02-4b2e-938f-9b53def0237f">
                     <id root="c643c2ef-e258-4a0b-a126-130a258a946a"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Of the 10,275 patients in clinical studies with rosuvastatin tablets, 3,159 (31%) were 65 years and older, and 698 (6.8%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects.</paragraph>
                        <paragraph>Advanced age (â¥65 years) is a risk factor for rosuvastatin tablets-associated myopathy and rhabdomyolysis. Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receivingÂ rosuvastatin tablets for the increased risk of myopathy <content styleCode="italics">[see <linkHtml href="#ID_149e50ef-0d0b-4f40-b1c3-d8b38843366a">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a3054989-2947-4434-9202-7cac8b00d71f">
                     <id root="e3db71e0-17e4-4095-8c34-214c178f3c22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment </title>
                     <text>
                        <paragraph>Rosuvastatin exposure is not influenced by mild to moderate renal impairment (CLcr â¥30 mL/min/1.73 m<sup>2</sup>). Exposure to rosuvastatin is increased to a clinically significant extent in patients with severe renal impairment (CLcr &lt;30 mL/min/1.73 m<sup>2</sup>) who are not receiving hemodialysis <content styleCode="italics">[see <linkHtml href="#ID_c0ada22f-7299-4bd7-a1d9-1134fd2612ff">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>Renal impairment is a risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy. In patients with severe renal impairment not on hemodialysis, the recommended starting dosage is 5 mg daily and should not exceed 10 mg daily <content styleCode="italics">[see <linkHtml href="#ID_b5a01c17-299c-44aa-8504-5ec5628ca1f4">Dosage and Administration (2.5)</linkHtml> and <linkHtml href="#ID_149e50ef-0d0b-4f40-b1c3-d8b38843366a">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6f2a4150-06d9-4238-8e34-0870057073e7">
                     <id root="39950ba1-b574-47d6-b677-1afb1f44df91"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Hepatic Impairment </title>
                     <text>
                        <paragraph>Rosuvastatin tabletsÂ are contraindicated in patients with acute liver failure or decompensated cirrhosis. Chronic alcohol liver disease is known to increase rosuvastatin exposure. Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury <content styleCode="italics">[see <linkHtml href="#ID_07d6d429-7e43-49f5-b63b-60ffc7e72566">Contraindications (4)</linkHtml>, <linkHtml href="#ID_2d070474-0c2b-41ba-a0a0-2d01988bdddf">Warning and Precautions (5.3)</linkHtml> and <linkHtml href="#ID_c0ada22f-7299-4bd7-a1d9-1134fd2612ff">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_8f018e35-3ee2-4090-a9c6-997d4f8c76a6">
                     <id root="ae1318c8-5395-47be-9fc7-a41d92c043bc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.8 Asian Patients </title>
                     <text>
                        <paragraph>Pharmacokinetic studies have demonstrated an approximate 2âfold increase in median exposure to rosuvastatin in Asian subjects when compared with White controls. Adjust the rosuvastatin tablets dosage in Asian patients<content styleCode="italics"> [see <linkHtml href="#ID_3f8a0510-38d1-4e61-9eff-e8bc8324913a">Dosage and Administration (2.4)</linkHtml> and <linkHtml href="#ID_c0ada22f-7299-4bd7-a1d9-1134fd2612ff">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_608bb9ea-cc13-407b-94ce-13be077f2482">
               <id root="eb405dd0-84cf-423d-b428-98eab6c8e960"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>No specific antidotes forÂ rosuvastatin tablets are known. Hemodialysis does not significantly enhance clearance of rosuvastatin. In the event of overdose, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.</paragraph>
               </text>
               <effectiveTime value="20250228"/>
            </section>
         </component>
         <component>
            <section ID="ID_c3b78b6b-8ad2-46c0-bedd-380ee52aba00">
               <id root="853b240d-7d81-4a34-8008-65768819193a"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)-reductase inhibitor.</paragraph>
                  <paragraph>The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="ID_0164685b-a774-471d-9cfa-8d542faeada7"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>The empirical formula for rosuvastatin calcium is (C<sub>22</sub>H<sub>27</sub>FN<sub>3</sub>O<sub>6</sub>S)<sub>2</sub>Ca and the molecular weight is 1,001.14. Rosuvastatin calcium is a white amorphous powder that is sparingly soluble in water and methanol, and slightly soluble in ethanol. Rosuvastatin calcium is a hydrophilic compound with a partition coefficient (octanol/water) of 0.13 at pH of 7.0.</paragraph>
                  <paragraph>RosuvastatinÂ tablets for oral use contain rosuvastatin 5 mg, 10 mg, 20 mg, or 40 mg (equivalent to 5.2 mg, 10.4 mg, 20.8 mg, and 41.6 mg rosuvastatin calcium) and the following inactive ingredients: microcrystalline cellulose NF, lactose monohydrate NF, anhydrous dibasic calcium phosphate USP, crospovidone NF, magnesium stearate NF, hypromellose USP, titanium dioxide USP, triacetin USP, yellow ferric oxide NF (rosuvastatin tablets, 5 mg and 20 mg), red ferric oxide NF (rosuvastatin tablets, 10 mg and 40 mg).</paragraph>
               </text>
               <effectiveTime value="20250228"/>
               <component>
                  <observationMedia ID="ID_0164685b-a774-471d-9cfa-8d542faeada7">
                     <text>structural</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="rosuvastatintablet-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8ac9ea56-4087-44c8-bce3-ef574a6ad2f9">
               <id root="f494e1e2-c9ac-48e1-8bee-898c607d5dd7"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20250228"/>
               <component>
                  <section ID="ID_fd674746-d0e7-4e46-8245-532d76fdb8f0">
                     <id root="81d8be71-d2ad-4462-bc5f-0cef58c43b96"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>Rosuvastatin tablets areÂ an inhibitor of HMGâCoA reductase, the rate-limiting enzyme that converts 3âhydroxyâ3âmethylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_07584b3e-e2ad-4f8d-9d8e-66578f612f57">
                     <id root="62c618b3-5ca4-4e9c-a06c-33bd0533bb78"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>Inhibition of HMG-CoA reductase by rosuvastatin accelerates the expression of LDL-receptors, followed by the uptake of LDL-C from blood to the liver, leading to a decrease in plasma LDL-C and total cholesterol. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very-low-density lipoproteins. The maximum LDL-C reduction ofÂ rosuvastatin tablets are usually achieved by 4 weeks and is maintained after that.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_c0ada22f-7299-4bd7-a1d9-1134fd2612ff">
                     <id root="e1c39a8f-5b43-4336-b199-a9f8fb2cbc01"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>In clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3 to 5 hours following oral dosing. Both C<sub>max</sub> and AUC increased in approximate proportion toÂ rosuvastatin tablets dose. The absolute bioavailability of rosuvastatin is approximately 20%. The AUC of rosuvastatin does not differ following evening or morning drug administration.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of food</content>
                        </paragraph>
                        <paragraph>Administration ofÂ rosuvastatin tablets with food did not affect the AUC of rosuvastatin.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Mean volume of distribution at steady-state of rosuvastatin is approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma concentrations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450Â \Â 2C9, and <content styleCode="italics">in vitro</content> studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMGâCoA reductase inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMGâCoA reductase inhibitory activity is accounted for by the parent compound.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route. The elimination half-life of rosuvastatin is approximately 19 hours.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Geriatric Patients</content>
                        </paragraph>
                        <paragraph>There were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly populations (age â¥65 years).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>In a population pharmacokinetic analysis of two pediatric trials involving patients with HeFH 10 to 17 years of age and 8 to 17 years of age, respectively, rosuvastatin exposure appeared comparable to or lower than rosuvastatin exposure in adult patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Male and Female Patients</content>
                        </paragraph>
                        <paragraph>There were no differences in plasma concentrations of rosuvastatin between males and females.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Racial or Ethnic Groups</content>
                        </paragraph>
                        <paragraph>A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among White, Hispanic or Latino ethnicity, and Black or Afro-Caribbean groups. However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate 2- fold elevation in median exposure (AUC and C<sub>max)</sub> in Asian subjects when compared with a White control group.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>Mild to moderate renal impairment (CL<sub>cr</sub> â¥30 mL/min/1.73 m<sup>2</sup>) had no influence on plasma concentrations of rosuvastatin. However, plasma concentrations of rosuvastatin increased to a clinically significant extent (about 3âfold) in patients with severe renal impairment (CL<sub>cr</sub> &lt;30 mL/min/1.73 m<sup>2</sup>) not receiving hemodialysis compared with healthy subjects (CL<sub>cr</sub> &gt;80 mL/min/1.73 m<sup>2</sup>).</paragraph>
                        <paragraph>Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were approximately 50% greater compared with healthy volunteer subjects with normal renal function.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>In patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly increased.</paragraph>
                        <paragraph>In patients with ChildâPugh A disease, C<sub>max</sub> and AUC were increased by 60% and 5%, respectively, as compared with patients with normal liver function. In patients with ChildâPugh B disease, C<sub>max</sub> and AUC were increased 100% and 21%, respectively, compared with patients with normal liver function.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions Studies</content>
                        </paragraph>
                        <paragraph>Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent.</paragraph>
                        <paragraph>Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein (BCRP). Concomitant administration ofÂ rosuvastatin tablets with medications that are inhibitors of these transporter proteins (e.g., cyclosporine, certain HIV protease inhibitors <content styleCode="italics">[see <linkHtml href="#ID_f954dfd4-4729-4787-ba58-79814a4fa6a8">Dosage and Administration (2.6)</linkHtml> and <linkHtml href="#ID_b68001d0-9698-48d8-a06d-15a265894e79">Drug Interactions (7.1)</linkHtml>] and ticagrelor [see <linkHtml href="#ID_b68001d0-9698-48d8-a06d-15a265894e79">Drug Interactions (7.1)]</linkHtml>)</content> may result in increased rosuvastatin plasma concentrations.</paragraph>
                        <table ID="_RefID0EZLAI" width="100%">
                           <caption>Table 8: Effect of Coadministered Drugs on Rosuvastatin Systemic Exposure</caption>
                           <colgroup>
                              <col width="43%"/>
                              <col width="19%"/>
                              <col width="19%"/>
                              <col width="20%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                                    <content styleCode="bold">Coadministered drug and dosing regimen</content>
                                 </th>
                                 <th styleCode="Botrule Lrule Rrule Toprule" colspan="3" align="center" valign="top">
                                    <content styleCode="bold">Rosuvastatin</content>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule" align="left" valign="top"/>
                                 <th styleCode="Botrule Lrule Rrule" align="left" valign="top"/>
                                 <th styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                                    <content styleCode="bold">Mean Ratio </content>
                                    <br/>
                                    <content styleCode="bold">(ratio with/without coadministered drug) </content>
                                    <br/>
                                    <content styleCode="bold">No Effect=1.0</content>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule" align="left" valign="top"/>
                                 <th styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">Dose (mg)</content>
                                    <footnote ID="_Ref92867300">Single dose unless otherwise noted.</footnote>
                                 </th>
                                 <th styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">Change in AUC</content>
                                 </th>
                                 <th styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">Change in C<sub>max</sub>
                                    </content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>Sofosbuvir/velpatasvir/voxilaprevir (400 mg-100 mg-100 mg) + Voxilaprevir (100 mg) once daily for 15 days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>10 mg, single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                                    <paragraph>7.39<footnote ID="_Ref92867317">Clinically significant <content styleCode="italics">[see <linkHtml href="#ID_c0650ff0-6f19-4b9a-be5a-0db2e0d6804a">Dosage and Administration (2)</linkHtml> and <linkHtml href="#ID_8feb70a7-5e35-44a2-bf85-1b10b3e7ebe8">Warnings and Precautions (5)</linkHtml>]</content>
                                       </footnote>
                                    </paragraph>
                                    <paragraph>(6.68 to 8.18)<footnote ID="_Ref92867343">Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7 = 30% decrease, 11=11âfold increase in exposure)</footnote>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="middle">
                                    <paragraph>18.88<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(16.23 to 21.96)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Cyclosporine â stable dose required (75Â mg â 200Â mgÂ BID)</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>10Â mg, QD for 10Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>7.1<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>11<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Darolutamide 600 mg BID, 5 days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>5 mg, single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>5.2<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>~5<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Regorafenib 160 mg QD, 14 days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>5 mg, single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>3.8<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>4.6<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Atazanavir/ritonavir combination 300Â mg/100Â mgÂ QD for 8Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10Â mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>3.1<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>7<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Simeprevir 150Â mg QD, 7Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10Â mg, single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.8<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(2.3 to 3.4)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>3.2<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(2.6 to 3.9)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Velpatasvir 100 mg once daily</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10 mg, single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.69<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(2.46 to 2.94)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.61<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(2.32 to 2.92)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Ombitasvir 25 mg/paritaprevir 150 mg/ ritonavir 100 mg + dasabuvir 400 mg BID</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>5 mg, single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.59<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(2.09 to 3.21)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>7.13<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(5.11 to 9.96)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Teriflunomide</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>Not available</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.51<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.65<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Enasidenib 100 mg QD, 28 days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10 mg, single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.44</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>3.66</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Elbasvir 50 mg/grazoprevir 200 mg once daily</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10 mg, single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.26<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(1.89 to 2.69)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>5.49<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(4.29 to 7.04)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Glecaprevir 400 mg/pibrentasvir 120 mg once daily</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>5 mg, once daily</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.15<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(1.88 to 2.46)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>5.62<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(4.80 to 6.59)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Lopinavir/ritonavir combination 400Â mg/100Â mgÂ BID for 17Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>20Â mg,Â QD for 7Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.1<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(1.7 to 2.6)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>5<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(3.4 to 6.4)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Capmatinib 400 mg BID</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10 mg, single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.08<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(1.56 to 2.76)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>3.04<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(2.36 to 3.92)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Fostamatinib 100 mg BID</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>20 mg, single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.96<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(1.77 to 2.15)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.88<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(1.69 to 2.09)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Febuxostat 120 mg QD for 4 days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10 mg, single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.9<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(1.5 to 2.5)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.1<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(1.8 to 2.6)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Gemfibrozil 600Â mgÂ BID for 7Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>80Â mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.9<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(1.6 to 2.2)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.2<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(1.8 to 2.7)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Tafamidis 61 mg BID on Days 1 &amp; 2, followed by QD on Days 3 to 9</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10 mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.97<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(1.68 to 2.31)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.86<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(1.59 to 2.16)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Eltrombopag 75Â mgÂ QD, 5Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10 mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.6</paragraph>
                                    <paragraph>(1.4 to 1.7)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2</paragraph>
                                    <paragraph>(1.8 to 2.3)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Darunavir 600Â mg/ritonavir 100Â mg BID, 7Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10 mg, QD for 7 days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.5</paragraph>
                                    <paragraph>(1.0 to 2.1)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.4</paragraph>
                                    <paragraph>(1.6 to 3.6)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Tipranavir/ritonavir combination 500Â mg/200 mgÂ BID for 11Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10Â mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.4</paragraph>
                                    <paragraph>(1.2 to 1.6)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>2.2</paragraph>
                                    <paragraph>(1.8 to 2.7)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Dronedarone 400Â mg BID</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10Â mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.4</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Itraconazole 200Â mgÂ QD, 5Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10Â mg or 80Â mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.4</paragraph>
                                    <paragraph>(1.2 to 1.6)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                    <paragraph>1.3</paragraph>
                                    <paragraph>(1.1 to 1.4)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.4</paragraph>
                                    <paragraph>(1.2 to 1.5)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                    <paragraph>1.2</paragraph>
                                    <paragraph>(0.9 to 1.4)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Ezetimibe 10Â mg QD, 14Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10Â mg, QD for 14Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="middle">1.2(0.9 to 1.6)<footnoteRef IDREF="_Ref92867343"/>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.2</paragraph>
                                    <paragraph>(0.8 to 1.6)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Fosamprenavir/ritonavir 700Â mg/100Â mgÂ BID for 7Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10Â mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.1</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Fenofibrate 67Â mgÂ TID for 7Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>10Â mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>â</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>1.2</paragraph>
                                    <paragraph>(1.1 to 1.3)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Rifampicin 450Â mgÂ QD, 7Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>20Â mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>â</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="middle"/>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Aluminum &amp; magnesium hydroxide combination antacid</paragraph>
                                    <paragraph>Administered simultaneously<br/>Administered 2Â hours apart</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>40Â mg<br/>40Â mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                                    <paragraph>0.5<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(0.4 to 0.5)<footnoteRef IDREF="_Ref92867343"/>
                                       <br/>0.8</paragraph>
                                    <paragraph>(0.7 to 0.9)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>0.5<footnoteRef IDREF="_Ref92867317"/>
                                    </paragraph>
                                    <paragraph>(0.4 to 0.6)<footnoteRef IDREF="_Ref92867343"/>
                                       <br/>0.8</paragraph>
                                    <paragraph>(0.7 to 1.0)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Ketoconazole 200Â mgÂ BID for 7Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>80Â mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>1.0</paragraph>
                                    <paragraph>(0.8 to 1.2)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>1.0</paragraph>
                                    <paragraph>(0.7 to 1.3)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Fluconazole 200Â mgÂ QD for 11Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>80Â mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>1.1</paragraph>
                                    <paragraph>(1.0 to 1.3)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>1.1</paragraph>
                                    <paragraph>(0.9 to 1.4)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Erythromycin 500Â mgÂ QID for 7Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>80Â mg</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>0.8</paragraph>
                                    <paragraph>(0.7 to 0.9)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>0.7</paragraph>
                                    <paragraph>(0.5 to 0.9)<footnoteRef IDREF="_Ref92867343"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" colspan="4" valign="top">
                                    <paragraph>QD= Once daily, BID= Twice daily, TID= Three times daily, QID= Four times daily</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="_RefID0E1LBI" width="100%">
                           <caption>Table 9: Effect of Rosuvastatin Coadministration on Systemic Exposure to Other Drugs</caption>
                           <colgroup>
                              <col width="22%"/>
                              <col width="48%"/>
                              <col width="15%"/>
                              <col width="15%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                                    <content styleCode="bold">Rosuvastatin Dosage Regimen</content>
                                 </th>
                                 <th styleCode="Botrule Lrule Rrule Toprule" colspan="3" align="left" valign="top">
                                    <content styleCode="bold">Coadministered Drug</content>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule" align="left" valign="top"/>
                                 <th styleCode="Botrule Lrule Rrule" align="left" valign="top"/>
                                 <th styleCode="Botrule Lrule Rrule" colspan="2" align="left" valign="top">
                                    <content styleCode="bold">Mean Ratio </content>
                                    <br/>
                                    <content styleCode="bold">(ratio with/without coadministered drug) </content>
                                    <br/>
                                    <content styleCode="bold">No Effect=1.0</content>
                                 </th>
                              </tr>
                              <tr>
                                 <th styleCode="Botrule Lrule Rrule" align="left" valign="top"/>
                                 <th styleCode="Botrule Lrule Rrule" align="left" valign="top">
                                    <content styleCode="bold">Name and Dose</content>
                                 </th>
                                 <th styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">Change in AUC</content>
                                 </th>
                                 <th styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <content styleCode="bold">Change in C<sub>max</sub>
                                    </content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>40Â mg QD for 10Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                                    <paragraph>Warfarin<footnote ID="_Ref92875026">Clinically significant pharmacodynamic effects <content styleCode="italics">[see <linkHtml href="#ID_243c2e29-7c8e-488b-a4f7-fd0ca69571ff">Drug Interactions (7.3)</linkHtml>]</content>
                                       </footnote>
                                    </paragraph>
                                    <paragraph>25Â mg single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>R-Warfarin</paragraph>
                                    <paragraph>1.0</paragraph>
                                    <paragraph>(1.0 to 1.1)<footnote ID="_Ref92875040">Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7=30% decrease, 11=11âfold increase in exposure)</footnote>
                                    </paragraph>
                                    <paragraph>S-Warfarin</paragraph>
                                    <paragraph>1.1</paragraph>
                                    <paragraph>(1.0 to 1.1)<footnoteRef IDREF="_Ref92875040"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                                    <paragraph>R-Warfarin</paragraph>
                                    <paragraph>1.0</paragraph>
                                    <paragraph>(0.9 to 1.0)<footnoteRef IDREF="_Ref92875040"/>
                                    </paragraph>
                                    <paragraph>S-Warfarin</paragraph>
                                    <paragraph>1.0</paragraph>
                                    <paragraph>(0.9 to 1.1)<footnoteRef IDREF="_Ref92875040"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>40Â mg QD for 12Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Digoxin</paragraph>
                                    <paragraph>0.5Â mg single dose</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>1.0</paragraph>
                                    <paragraph>(0.9 to 1.2)<footnoteRef IDREF="_Ref92875040"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>1.0</paragraph>
                                    <paragraph>(0.9 to 1.2)<footnoteRef IDREF="_Ref92875040"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>40Â mg QD for 28Â days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" valign="top">
                                    <paragraph>Oral Contraceptive</paragraph>
                                    <paragraph>(ethinyl estradiol 0.035Â mg &amp; norgestrel 0.180, 0.215 and 0.250Â mg) QD for 21Â Days</paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>EE 1.3</paragraph>
                                    <paragraph>(1.2 to 1.3)<footnoteRef IDREF="_Ref92875040"/>
                                    </paragraph>
                                    <paragraph>NG 1.3</paragraph>
                                    <paragraph>(1.3 to 1.4)<footnoteRef IDREF="_Ref92875040"/>
                                    </paragraph>
                                 </td>
                                 <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                                    <paragraph>EE 1.3</paragraph>
                                    <paragraph>(1.2 to 1.3)<footnoteRef IDREF="_Ref92875040"/>
                                    </paragraph>
                                    <paragraph>NG 1.2</paragraph>
                                    <paragraph>(1.1 to 1.3)<footnoteRef IDREF="_Ref92875040"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule" colspan="4" valign="top">
                                    <paragraph>EE = ethinyl estradiol, NG = norgestrel, QD= Once daily</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b2a8c0d9-4e7f-4f3b-a56c-5a70e082536f">
                     <id root="10b0ed89-4a7e-4618-919e-d2353ced97cf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.5 Pharmacogenomics </title>
                     <text>
                        <paragraph>Disposition of rosuvastatin, involves OATP1B1 and other transporter proteins. Higher plasma concentrations of rosuvastatin have been reported in very small groups of patients (n=3 to 5) who have two reduced function alleles of the gene that encodes OATP1B1 (<content styleCode="italics">SLCO1B1</content> 521T &gt; C). The frequency of this genotype (i.e., <content styleCode="italics">SLCO1B1</content> 521 C/C) is generally lower than 5% in most racial/ethnic groups. The impact of this polymorphism on efficacy and/or safety ofÂ rosuvastatin has not been clearly established.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_5c81ec44-b963-4bc7-bdfe-ccd1c6783b67">
               <id root="ad9aab4f-17f4-4f14-bbe5-040ba2be3ddd"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY </title>
               <effectiveTime value="20250228"/>
               <component>
                  <section ID="ID_6c8c4fc8-ae49-4401-b462-a66d7a6a0345">
                     <id root="26737825-3f42-412d-82f6-58105e95c9b9"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility </title>
                     <text>
                        <paragraph>In a 104âweek carcinogenicity study in rats at dose levels of 2, 20, 60, or 80 mg/kg/day by oral gavage, the incidence of uterine stromal polyps was significantly increased in females at 80 mg/kg/day at systemic exposure 20 times the human exposure at 40 mg/day based on AUC. Increased incidence of polyps was not seen at lower doses.</paragraph>
                        <paragraph>In a 107âweek carcinogenicity study in mice given 10, 60, or 200 mg/kg/day by oral gavage, an increased incidence of hepatocellular adenoma/carcinoma was observed at 200 mg/kg/day at systemic exposures 20 times the human exposure at 40 mg/day based on AUC. An increased incidence of hepatocellular tumors was not seen at lower doses.</paragraph>
                        <paragraph>Rosuvastatin was not mutagenic or clastogenic with or without metabolic activation in the Ames test with <content styleCode="italics">Salmonella typhimurium and Escherichia coli,</content> the mouse lymphoma assay, and the chromosomal aberration assay in Chinese hamster lung cells. Rosuvastatin was negative in the <content styleCode="italics">in vivo</content> mouse micronucleus test.</paragraph>
                        <paragraph>In rat fertility studies with oral gavage doses of 5, 15, 50 mg/kg/day, males were treated for 9 weeks prior to and throughout mating and females were treated 2 weeks prior to mating and throughout mating until gestation day 7. No adverse effect on fertility was observed at 50 mg/kg/day (systemic exposures up to 10 times the human exposure at 40 mg/day based on AUC). In testicles of dogs treated with rosuvastatin at 30 mg/kg/day for one month, spermatidic giant cells were seen. Spermatidic giant cells were observed in monkeys after 6âmonth treatment at 30 mg/kg/day in addition to vacuolation of seminiferous tubular epithelium. Exposures in the dog were 20 times and in the monkey 10 times the human exposure at 40 mg/day based on body surface area. Similar findings have been seen with other drugs in this class.</paragraph>
                     </text>
                     <effectiveTime value="20250228"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_87f36f0e-09d0-4356-8575-7cd6a0114a6a">
               <id root="ffcdb870-c677-42d0-a99d-8eddb625c3b1"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Primary Prevention of CV Disease</content>
                  </paragraph>
                  <paragraph>In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect ofÂ rosuvastatin on the occurrence of major CV disease events was assessed in 17,802 males (â¥50 years) and females (â¥60 years) who had no clinically evident CV disease, LDLâC levels &lt;130 mg/dL and hsCRP levels â¥2 mg/L. The study population had an estimated baseline coronary heart disease risk of 11.6% over 10 years based on the Framingham risk criteria and included a high percentage of patients with additional risk factors such as hypertension (58%), low HDLâC levels (23%), cigarette smoking (16%), or a family history of premature CHD (12%). Patients had a median baseline LDLâC of 108 mg/dL and hsCRP of 4.3 mg/L. Patients were randomly assigned to placebo (n=8901) orÂ rosuvastatin 20Â mg once daily (n=8901) and were followed for a mean duration of 2 years. The JUPITER study was stopped early by the Data Safety Monitoring Board due to meeting predefined stopping rules for efficacy in rosuvastatin-treated subjects.</paragraph>
                  <paragraph>The primary end point was a composite end point consisting of the time-to-first occurrence of any of the following major CV events: CV death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina or an arterial revascularization procedure.</paragraph>
                  <paragraph>Rosuvastatin significantly reduced the risk of major CV events (252 events in the placebo group vs. 142 events in the rosuvastatin group) with a statistically significant (p&lt;0.001) relative risk reduction of 44% and absolute risk reduction of 1.2% (see Figure 1). The risk reduction for the primary end point was consistent across the following predefined subgroups: age, sex, race, smoking status, family history of premature CHD, body mass index, LDLâC, HDLâC, and hsCRP levels.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1. Time to First Occurrence of Major CV Events in JUPITER</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="ID_394dd986-9b1b-415c-b8e8-edc917d6f2df"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>The individual components of the primary end point are presented in Figure 3.Â Rosuvastatin significantly reduced the risk of nonfatal myocardial infarction, nonfatal stroke, and arterial revascularization procedures. There were no significant treatment differences between theÂ rosuvastatin and placebo groups for death due to CV causes or hospitalizations for unstable angina.</paragraph>
                  <paragraph>RosuvastatinÂ significantly reduced the risk of myocardial infarction (6 fatal events and 62 nonfatal events in placebo-treated subjects vs. 9 fatal events and 22 nonfatal events in rosuvastatin-treated subjects) and the risk of stroke (6 fatal events and 58 nonfatal events in placebo-treated subjects vs. 3 fatal events and 30 nonfatal events in rosuvastatin-treated subjects).</paragraph>
                  <paragraph>In a post-hoc subgroup analysis of JUPITER subjects (rosuvastatin=725, placebo=680) with a hsCRP â¥2 mg/L and no other traditional risk factors (smoking, BP â¥140/90 or taking antihypertensives, low HDLâC) other than age, after adjustment for high HDLâC, there was no significant treatment benefit withÂ rosuvastatin treatment.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 2. Major CV Events by Treatment Group inÂ JUPITER</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="C08F9F32-FA39-48D7-9DFC-AD8CE87FE051"/>
                     </content>
                  </paragraph>
                  <paragraph>At one year,Â rosuvastatin increased HDLâC and reduced LDLâC, hsCRP, total cholesterol and serum triglyceride levels (p&lt;0.001 for all versus placebo).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Primary Hyperlipidemia in Adults</content>
                  </paragraph>
                  <paragraph>RosuvastatinÂ reduces TotalâC, LDLâC, ApoB, nonâHDLâC, and TG, and increases HDLâC, in adult patients with hyperlipidemia and mixed dyslipidemia.</paragraph>
                  <paragraph>In a multicenter, doubleâblind, placeboâcontrolled study in patients with hyperlipidemia, rosuvastatin given as a single daily dose (5 to 40 mg) for 6 weeks significantly reduced TotalâC, LDLâC, nonâHDLâC, and ApoB, across the dose range (Table 10).</paragraph>
                  <table ID="_RefID0E3WBI" width="100%">
                     <caption>Table 10: Lipid-Modifying Effect ofÂ Rosuvastatin in Adult Patients with Hyperlipidemia (Adjusted Mean % Change from Baseline at Week 6)</caption>
                     <colgroup>
                        <col width="29%"/>
                        <col width="7%"/>
                        <col width="12%"/>
                        <col width="11%"/>
                        <col width="16%"/>
                        <col width="8%"/>
                        <col width="7%"/>
                        <col width="11%"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="First Last">
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                              <content styleCode="bold">Dose</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <content styleCode="bold">N</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <content styleCode="bold">Total</content>â<content styleCode="bold">C</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <content styleCode="bold">LDL</content>â<content styleCode="bold">C</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <content styleCode="bold">Non-HDL</content>â<content styleCode="bold">C</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <content styleCode="bold">ApoB</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <content styleCode="bold">TG</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <content styleCode="bold">HDL</content>â<content styleCode="bold">C</content>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>Placebo</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>13</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>-5</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>-7</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>-7</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>-3</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>-3</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>3</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>rosuvastatin 5Â mg</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>17</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-33</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-45</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-44</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-38</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-35</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>13</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>rosuvastatinÂ 10Â mg</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>17</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-36</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-52</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-48</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-42</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-10</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>14</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>rosuvastatin 20Â mg</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>17</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-40</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-55</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-51</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-46</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-23</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>8</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>rosuvastatin 40Â mg</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>18</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-46</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-63</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-60</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-54</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-28</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>10</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>RosuvastatinÂ was compared with the statins (atorvastatin, simvastatin, and pravastatin) in a multicenter, open-label, doseâranging study of 2,240 patients with hyperlipidemia or mixed dyslipidemia. After randomization, patients were treated for 6 weeks with a single daily dose of either rosuvastatin, atorvastatin, simvastatin, or pravastatin (see Figure 3 and Table 11).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 3. Percent LDL</content>â<content styleCode="bold">C Change by Dose of Rosuvastatin, Atorvastatin, Simvastatin, and Pravastatin at Week 6 in Adult Patients with Hyperlipidemia or Mixed Dyslipidemia</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="B08BB823-9C9F-4769-991F-6EAFB0B85894"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>Box plots are a representation of the 25th, 50th, and 75th percentile values, with whiskers representing the 10th and 90th percentile values. Mean baseline LDLâC: 189 mg/dL.</paragraph>
                  <table ID="_RefID0EHACI" width="100%">
                     <caption>Table 11: Percent Change in LDL-C by Dose of Rosuvastatin, Atorvastatin, Simvastatin, and Pravastatin From Baseline to Week 6 (LS Mean<footnote ID="_Ref119925405">Corresponding standard errors are approximately 1.00.</footnote>) in Adult Patients with Hyperlipidemia or Mixed Dyslipidemia (Sample Sizes Ranging from 156â167 Patients Per Group)</caption>
                     <colgroup>
                        <col width="28%"/>
                        <col width="18%"/>
                        <col width="18%"/>
                        <col width="18%"/>
                        <col width="18%"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" colspan="4" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Treatment Daily Dose</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Treatment</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">10Â mg</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">20Â mg</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">40Â mg</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">80Â mg</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Rosuvastatin</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-46<footnote ID="_Ref119925449">Rosuvastatin 10 mg reduced LDL-C significantly more than atorvastatin 10 mg; pravastatin 10 mg, 20 mg, and 40 mg; simvastatin 10 mg, 20 mg, and 40 mg. (p&lt;0.002)</footnote>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-52<footnote ID="_Ref119925479">Rosuvastatin 20 mg reduced LDL-C significantly more than atorvastatin 20 mg and 40 mg; pravastatin 20 mg and 40 mg; simvastatin 20 mg, 40 mg, and 80 mg. (p&lt;0.002)</footnote>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-55<footnote ID="_Ref119925490">Rosuvastatin 40 mg reduced LDLâC significantly more than atorvastatin 40 mg; pravastatin 40 mg; simvastatin 40 mg, and 80 mg. (p&lt;0.002)</footnote>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>---</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Atorvastatin</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-37</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-43</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-48</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-51</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Simvastatin</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-28</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-35</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-39</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-46</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Pravastatin</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-20</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-24</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-30</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>---</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Slowing of the Progression of Atherosclerosis</content>
                  </paragraph>
                  <paragraph>In the <content styleCode="italics">Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg </content>
                     <content styleCode="italics">(METEOR)</content> study, the effect of therapy withÂ rosuvastatin on carotid atherosclerosis was assessed by B-mode ultrasonography in patients with elevated LDLâC, at low risk (Framingham risk &lt;10% over ten years) for symptomatic coronary artery disease and with subclinical atherosclerosis as evidenced by carotid intimal-medial thickness (cIMT). In this double-blind, placebo-controlled clinical study 984 adult patients were randomized (of whom 876 were analyzed) in a 5:2 ratio toÂ rosuvastatin 40 mg or placebo once daily. Ultrasonograms of the carotid walls were used to determine the annualized rate of change per patient from baseline to two years in mean maximum cIMT of 12 measured segments. The estimated difference in the rate of change in the maximum cIMT analyzed over all 12 carotid artery sites between patients treated withÂ rosuvastatinÂ and placebo-treated patients was -0.0145Â mm/year (95% CI â0.0196, â0.0093; p&lt;0.0001).</paragraph>
                  <paragraph>The annualized rate of change from baseline for the placebo group was +0.0131 mm/year (p&lt;0.0001). The annualized rate of change from baseline for the group treated withÂ rosuvastatin was -0.0014 mm/year (p=0.32).</paragraph>
                  <paragraph>At an individual patient level in the group treated with rosuvastatin, 52.1% of patients demonstrated an absence of disease progression (defined as a negative annualized rate of change), compared to 37.7% of patients in the placebo group.</paragraph>
                  <paragraph>
                     <content styleCode="underline">HeFH in Adults</content>
                  </paragraph>
                  <paragraph>In a study of adult patients with HeFH (baseline mean LDL of 291 mg/dL), patients were randomized toÂ rosuvastatin 20 mg or atorvastatin 20 mg. The dose was increased at 6-week intervals. Significant LDL-C reductions from baseline were seen at each dose in both treatment groups (see Table 12).</paragraph>
                  <table ID="_RefID0ETFCI" width="100%">
                     <caption>Table 12: LDL-C Percent Change from Baseline</caption>
                     <colgroup>
                        <col width="17%"/>
                        <col width="13%"/>
                        <col width="33%"/>
                        <col width="37%"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="First Last">
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top"/>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top"/>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                              <content styleCode="bold">RosuvastatinÂ (n=435)</content>
                              <br/>
                              <content styleCode="bold">LS Mean</content>
                              <footnote ID="_Ref119925756">LS Means are least square means adjusted for baseline LDL-C</footnote>
                              <content styleCode="bold"> (95% CI)</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                              <content styleCode="bold">Atorvastatin (n=187)</content>
                              <br/>
                              <content styleCode="bold"> LS Mean<content styleCode="italics">
                                    <sup>1</sup>
                                 </content> (95% CI)</content>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>Week 6</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>20Â mg</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>-47% (-49%, -46%)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>-38% (-40%, -36%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Week 12</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>40Â mg</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-55% (-57%, -54%)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-47% (-49%, -45%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Week 18</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>80Â mg</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>NA</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-52% (-54%, -50%)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">HeFH in Pediatric Patients</content>
                  </paragraph>
                  <paragraph>In a double-blind, randomized, multicenter, placebo-controlled, 12-week study, 176 (97 male and 79 female) pediatric patients with HeFH were randomized to rosuvastatin 5 mg, 10 mg or 20 mg or placebo daily. Patients ranged in age from 10 to 17 years (median age of 14 years) with approximately 30% of the patients 10 to 13 years and approximately 17%, 18%, 40%, and 25% at Tanner stages II, III, IV, and V, respectively. Females were at least 1-year postmenarche. Mean LDL-C at baseline was 233 mg/dL (range of 129 to 399). The 12-week double-blind phase was followed by a 40-week open-label dose-titration phase, where all patients (n=173) received 5 mg, 10 mg or 20 mg rosuvastatin daily.</paragraph>
                  <paragraph>Rosuvastatin significantly reduced LDL-C (primary end point), total cholesterol and ApoB levels at each dose compared to placebo. Results are shown in Table 13 below.</paragraph>
                  <table ID="_RefID0E6ICI" width="100%">
                     <caption>Table 13: Lipid-Modifying Effects ofÂ RosuvastatinÂ  in Pediatric Patients 10 to 17 years of Age with HeFH (Least-Squares Mean Percent Change from Baseline To Week 12)</caption>
                     <colgroup>
                        <col width="20%"/>
                        <col width="13%"/>
                        <col width="15%"/>
                        <col width="13%"/>
                        <col width="13%"/>
                        <col width="11%"/>
                        <col width="15%"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="First Last">
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                              <content styleCode="bold">Dose (mg)</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                              <content styleCode="bold">N</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                              <content styleCode="bold">LDL</content>â<content styleCode="bold">C</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                              <content styleCode="bold">HDL</content>â<content styleCode="bold">C</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                              <content styleCode="bold">Total</content>â<content styleCode="bold">C</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                              <content styleCode="bold">TG</content>
                              <footnote ID="_Ref119926127">Median percent change</footnote>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                              <content styleCode="bold">ApoB</content>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>Placebo</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>46</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>-1%</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>+7%</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>0%</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>-7%</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>-2%</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>5</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>42</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-38%</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>+4%<footnote ID="_Ref119926193">Difference from placebo not statistically significant</footnote>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-30%</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-13%<footnoteRef IDREF="_Ref119926193"/>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-32%</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>10</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>44</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-45%</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>+11%<footnoteRef IDREF="_Ref119926193"/>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-34%</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-15%<footnoteRef IDREF="_Ref119926193"/>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-38%</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>20</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>44</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-50%</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>+9%<footnoteRef IDREF="_Ref119926193"/>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-39%</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>16%<footnoteRef IDREF="_Ref119926193"/>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-41%</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Rosuvastatin was also studied in a two-year openâlabel, uncontrolled, titration-to-goal trial that included 175 pediatric patients with HeFH who were 8 to 17 years old (79 males and 96 females). All patients had a documented genetic defect in the LDL receptor or in ApoB. Approximately 89% were White, 7% were Asian, 1% were Black or African American, and fewer than 1% were Hispanic or Latino ethnicity. Mean LDL-C at baseline was 236 mg/dL. Fifty-eight (33%) patients were prepubertal at baseline. The starting rosuvastatin dosage for all pediatric patients was 5 mg once daily. Pediatric patients aged 8 to less than 10 years (n=41 at baseline) could titrate to a maximum dosage of 10 mg once daily, and pediatric patients aged 10 to 17 years could titrate to a maximum dosage of 20 mg once daily.</paragraph>
                  <paragraph>The reductions in LDLâC from baseline were generally consistent across age groups within the trial as well as with previous experience in both adult and pediatric controlled trials.</paragraph>
                  <paragraph>
                     <content styleCode="underline">HoFH in Adult and Pediatric Patients</content>
                  </paragraph>
                  <paragraph>In an open-label, forced-titration study, HoFH patients (n=40, 8â63 years) were evaluated for their response toÂ rosuvastatin 20 to 40 mg titrated at a 6âweek interval. In the overall population, the mean LDLâC reduction from baseline was 22%. About one-third of the patients benefited from increasing their dose from 20 mg to 40 mg with further LDLâC lowering of greater than 6%. In the 27 patients with at least a 15% reduction in LDLâC, the mean LDLâC reduction was 30% (median 28% reduction). Among 13 patients with an LDLâC reduction of &lt;15%, 3 had no change or an increase in LDLâC. Reductions in LDLâC of 15% or greater were observed in 3Â ofÂ 5 patients with known receptor negative status.</paragraph>
                  <paragraph>
                     <content styleCode="underline">HoFH in Pediatric Patients</content>
                  </paragraph>
                  <paragraph>RosuvastatinÂ was studied in a randomized, double-blind, placebo-controlled, multicenter, cross-over study in 14Â pediatric patients with HoFH. The study included a 4âweek dietary leadâin phase during which patients receivedÂ rosuvastatin 10 mg daily, a crossâover phase that included two 6âweek treatment periods with eitherÂ rosuvastatin 20 mg or placebo in random order, followed by a 12âweek openâlabel phase during which all patients receivedÂ rosuvastatin 20 mg. Patients ranged in age from 7 to 15 years of age (median 11 years), 50% were male, 71% were White, 21% were Asian, 7% were Black or African American, and no patients were of Hispanic or Latino ethnicity. Fifty percent were on apheresis therapy and 57% were taking ezetimibe. Patients who entered the study on apheresis therapy or ezetimibe continued the treatment throughout the entire study. Mean LDL-C at baseline was 416 mg/dL (range 152 to 716 mg/dL). A total of 13 patients completed both treatment periods of the randomized cross-over phase; one patient withdrew consent due to inability to have blood drawn during the cross-over phase.</paragraph>
                  <paragraph>RosuvastatinÂ 20 mg significantly reduced LDL-C, total cholesterol, ApoB, and non-HDL-C compared to placebo (see Table 14).</paragraph>
                  <table ID="_RefID0EBRCI" width="100%">
                     <caption>Table 14: Lipid-Modifying Effects ofÂ Rosuvastatin in Pediatric Patients 7 to 15 years of Age with HoFH After 6 Weeks</caption>
                     <colgroup>
                        <col width="24%"/>
                        <col width="17%"/>
                        <col width="24%"/>
                        <col width="36%"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top"/>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
                              <paragraph>
                                 <content styleCode="bold">Placebo</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(N=13)</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="bottom">
                              <paragraph>
                                 <content styleCode="bold">RosuvastatinÂ 20Â mg</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(N=13)</content>
                              </paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Percent difference (95% CI)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>LDL-C (mg/dL)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                              <paragraph>481</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                              <paragraph>396</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-22.3% (-33.5, -9.1)<footnote ID="_Ref119927054">p=0.005</footnote>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Total-C (mg/dL)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                              <paragraph>539</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                              <paragraph>448</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-20.1% (-29.7, -9.1)<footnote ID="_Ref119927063">p=0.003</footnote>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Non-HDL-C (mg/dL)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                              <paragraph>505</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>412</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                              <paragraph>-22.9% (-33.7, â10.3)<footnoteRef IDREF="_Ref119927063"/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>ApoB (mg/dL)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="middle">
                              <paragraph>268</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>235</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-17.1% (-29.2, -2.9)<footnote ID="_Ref119927098"> p=0.024</footnote>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" colspan="4" valign="top">
                              <paragraph>% Difference estimates are based on transformations of the estimated mean difference in log LDL measurements betweenÂ rosuvastatin and placebo using a mixed model adjusted for study period</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Primary Dysbetalipoproteinemia in Adults</content>
                  </paragraph>
                  <paragraph>In a randomized, multicenter, double-blind crossover-study, 32 adult patients (27 with Ñ2/Ñ2 and 4 with apo E mutation [Arg145Cys] with primary dysbetalipoproteinemia entered a 6âweek dietary lead-in period on the NCEP Therapeutic Lifestyle Change (TLC) diet. Following dietary lead-in, patients were randomized to a sequence of treatments for 6 weeks each: rosuvastatin 10 mg followed by rosuvastatin 20 mg or rosuvastatin 20 mg followed by rosuvastatin 10 mg.Â Rosuvastatin reduced non-HDLâC (primary end point) and circulating remnant lipoprotein levels. Results are shown in the table below.</paragraph>
                  <table ID="_RefID0EYVCI" width="100%">
                     <caption>Table 15: Lipid-Modifying Effects ofÂ Rosuvastatin 10 mg and 20 mg in Adult Patients with Primary Dysbetalipoproteinemia (Type III hyperlipoproteinemia) After Six Weeks by Median Percent Change (95% CI) from Baseline (N=32)</caption>
                     <colgroup>
                        <col width="22%"/>
                        <col width="15%"/>
                        <col width="30%"/>
                        <col width="33%"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="First Last">
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top"/>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <content styleCode="bold">Median at Baseline (mg/dL)</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <content styleCode="bold">Median percent change from baseline (95% CI)</content>
                              <br/>
                              <content styleCode="bold">RosuvastatinÂ 10Â mg</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <content styleCode="bold">Median percent change from baseline (95% CI)</content>
                              <br/>
                              <content styleCode="bold">RosuvastatinÂ 20Â mg</content>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>TotalâC</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>342.5</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>-43.3</paragraph>
                              <paragraph>(-46.9, - 37.5)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>-47.6</paragraph>
                              <paragraph>(-51.6,-42.8)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Triglycerides</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>503.5</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-40.1</paragraph>
                              <paragraph>(-44.9, -33.6)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-43.0</paragraph>
                              <paragraph>(-52.5, -33.1)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Non-HDLâC</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>294.5</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-48.2</paragraph>
                              <paragraph>(-56.7, -45.6)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-56.4</paragraph>
                              <paragraph>(-61.4, -48.5)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>VLDLâC + IDLâC</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>209.5</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-46.8</paragraph>
                              <paragraph>(-53.7, -39.4)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-56.2</paragraph>
                              <paragraph>(-67.7, -43.7)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>LDLâC</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>112.5</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-54.4</paragraph>
                              <paragraph>(-59.1, -47.3)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-57.3</paragraph>
                              <paragraph>(-59.4, -52.1)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>HDLâC</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>35.5</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>10.2</paragraph>
                              <paragraph>(1.9, 12.3)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>11.2</paragraph>
                              <paragraph>(8.3, 20.5)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>RLPâC</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>82.0</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-56.4</paragraph>
                              <paragraph>(-67.1, -49.0)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-64.9</paragraph>
                              <paragraph>(-74.0, -56.6)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>ApoâE</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>16.0</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-42.9</paragraph>
                              <paragraph>(-46.3, -33.3)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>-42.5</paragraph>
                              <paragraph>(-47.1, -35.6)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Hypertriglyceridemia in Adults</content>
                  </paragraph>
                  <paragraph>In a double-blind, placebo-controlled study in adult patients with baseline TG levels from 273 to 817 mg/dL,Â rosuvastatinÂ given as a single daily dose (5 to 40 mg) over 6 weeks significantly reduced serum TG levels (see Table 16).</paragraph>
                  <table ID="_RefID0EN4CI" width="100%">
                     <caption>Table 16: Lipid-Modifying Effect ofÂ Rosuvastatin in Adult Patients with Primary Hypertriglyceridemia After Six Weeks by Median (Min, Max) Percent Change from Baseline to Week 6</caption>
                     <colgroup>
                        <col width="16%"/>
                        <col width="14%"/>
                        <col width="15%"/>
                        <col width="17%"/>
                        <col width="19%"/>
                        <col width="19%"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="First Last">
                           <th styleCode="Botrule Lrule Rrule Toprule" align="left" valign="top">
                              <content styleCode="bold">Dose</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <content styleCode="bold">Placebo </content>
                              <br/>
                              <content styleCode="bold">(n=26)</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">Rosuvastatin<br/>
                              <content styleCode="bold">5Â mg</content>
                              <br/>
                              <content styleCode="bold">(n=25)</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">Rosuvastatin<br/>
                              <content styleCode="bold">10Â mg </content>
                              <br/>
                              <content styleCode="bold">(n=23)</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">Rosuvastatin<br/>
                              <content styleCode="bold">20Â mg </content>
                              <br/>
                              <content styleCode="bold">(n=27)</content>
                           </th>
                           <th styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">Rosuvastatin<br/>
                              <content styleCode="bold">40Â mg </content>
                              <br/>
                              <content styleCode="bold">(n=25)</content>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" valign="top">
                              <paragraph>Triglycerides</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>1 (-40, 72)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>-21 (-58, 38)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>-37 (-65, 5)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>-37 (-72, 11)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>-43 (-80, -7)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Non-HDL-C</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>2 (-13, 19)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-29 (-43, -8)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-49 (-59, -20)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-43 (-74, 12)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-51 (-62, -6)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Total-C</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>1 (-13, 17)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-24 (-40, -4)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-40 (-51, -14)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-34 (-61, -11)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-40 (-51, -4)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>LDL-C</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>5 (-30, 52)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-28 (-71, 2)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-45 (-59, 7)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-31 (-66, 34)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-43 (-61, -3)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>HDL-C</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>-3 (-25, 18)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>3Â (-38, 33)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>8 (-8, 24)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>22 (-5, 50)</paragraph>
                           </td>
                           <td styleCode="Botrule Lrule Rrule" align="center" valign="top">
                              <paragraph>17 (-14, 63)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250228"/>
               <component>
                  <observationMedia ID="ID_394dd986-9b1b-415c-b8e8-edc917d6f2df">
                     <text>figure_1_time</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="rosuvastatintablet-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="C08F9F32-FA39-48D7-9DFC-AD8CE87FE051">
                     <text>figure_2-major</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="rosuvastatintablet-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="B08BB823-9C9F-4769-991F-6EAFB0B85894">
                     <text>figure_3_percent_dyslipidemia</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="rosuvastatintablet-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_fc84bca6-b6b4-4d1d-b244-38312481207e">
               <id root="ebf1aef1-bc78-4194-9eb1-a42515043b87"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>RosuvastatinÂ tablets are supplied as:</paragraph>
                  <paragraph>NDC 69434-005-02: 5mg. Round, yellow film coated tablet, biconvex, one side of the tablet debossedâY16â, the other side is smooth; bottle of 90 tablets.<br/>NDC 69434-005-03: 5mg. Round, yellow film coated tablet, biconvex, one side of the tablet debossed âY16â, the other side is smooth; bottle of 500 tablets.</paragraph>
                  <paragraph>NDC 69434-006-02: 10 mg. Round, pink film coated tablet, biconvex, one side of the tablet debossed âY17â, the other side is smooth; bottle of 90 tablets.<br/>NDC 69434-006-03: 10 mg. Round, pink film coated tablet, biconvex, one side of the tablet debossed âY17â, the other side is smooth; bottle of 500 tablets.</paragraph>
                  <paragraph>NDC 69434-007-02: 20 mg. Round, yellow film coated tablet, biconvex, one side of the tablet debossed âY19â, the other side is smooth; bottle of 90 tablets.<br/>NDC 69434-007-03: 20 mg. Round, yellow film coated tablet, biconvex, one side of the tablet debossed âY19â, the other side is smooth; bottle of 500 tablets.</paragraph>
                  <paragraph>NDC 69434-008-01: 40 mg. Round, pink film coated tablet, biconvex, one side of the tablet debossed âY20â, the other side is smooth; bottle of 30 tablets.<br/>NDC 69434-008-03: 40 mg. Round, pink film coated tablet, biconvex, one side of the tablet debossed âY20â, the other side is smooth; bottle of 500 tablets.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage</content>
                  </paragraph>
                  <paragraph>Store at controlled room temperature, 20ÂºC to 25ÂºC (68ÂºF to 77ÂºF); excursions permitted between 15Â°C and 30Â°C (59Â°F and 86Â°F) [see USP Controlled Room Temperature]. Protect from moisture.</paragraph>
               </text>
               <effectiveTime value="20250228"/>
            </section>
         </component>
         <component>
            <section ID="ID_660ff75c-74a9-4e96-9e49-23fed26e2b0a">
               <id root="ea837cf2-ac25-43cb-9041-46b3d8db772a"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>
                     <content styleCode="italics">Myopathy and Rhabdomyolysis</content>
                  </paragraph>
                  <paragraph>Advise patients thatÂ rosuvastatin tablets may cause myopathy and rhabdomyolysis. Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over-the-counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever <content styleCode="italics">[see <linkHtml href="#ID_149e50ef-0d0b-4f40-b1c3-d8b38843366a">Warnings and Precautions (5.1)</linkHtml>, and <linkHtml href="#ID_b68001d0-9698-48d8-a06d-15a265894e79">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hepatic Dysfunction</content>
                  </paragraph>
                  <paragraph>Inform patients thatÂ rosuvastatin tablets may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice <content styleCode="italics">[see <linkHtml href="#ID_2d070474-0c2b-41ba-a0a0-2d01988bdddf">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Increases in HbA1c and Fasting Serum Glucose Levels</content>
                  </paragraph>
                  <paragraph>Inform patients that increases in HbA1c and fasting serum glucose levels may occur with rosuvastatin tablets. Encourage patients to optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices <content styleCode="italics">[see <linkHtml href="#ID_d2f4af30-908e-4f9f-9477-fcc323906901">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Pregnancy</content>
                  </paragraph>
                  <paragraph>Advise pregnant patients and patients who can become pregnant of the potential risk to a fetus. Advise patients to inform their healthcare provider of a known or suspected pregnancy to discuss ifÂ rosuvastatin tablets should be discontinued <content styleCode="italics">[see <linkHtml href="#ID_c80a1e31-4f4c-4332-8d44-f96b9258cb21">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Lactation</content>
                  </paragraph>
                  <paragraph>Advise patients that breastfeeding during treatment withÂ rosuvastatin tablets are not recommended <content styleCode="italics">[see <linkHtml href="#ID_aec55442-b0d6-4ac8-99ff-80041069c027">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Concomitant Use of Antacids</content>
                  </paragraph>
                  <paragraph>When takingÂ rosuvastatin tablets with an aluminum and magnesium hydroxide combination antacid, administerÂ rosuvastatin tablets at least 2 hours before the antacid <content styleCode="italics">[see <linkHtml href="#ID_87add7e4-e73b-4d14-b5f6-77a36662e2d1">Drug Interactions (7.2)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Missed Doses</content>
                  </paragraph>
                  <paragraph>If a dose is missed, advise patients not take an extra dose. Just resume the usual schedule <content styleCode="italics">[see <linkHtml href="#ID_297c18c5-1dc3-4aed-a926-c2432b312de6">Dosage and Administration (2.1)</linkHtml>]</content>.</paragraph>
                  <paragraph>Rosuvastatin tablets are manufactured by Zhejiang Yongtai Pharmaceutical Co., Ltd.</paragraph>
                  <paragraph>Zhejiang Yongtai Pharmaceutical Co., Ltd.<br/>No.1, 8<sup>th</sup> Donghai Avenue, Zhejiang Provincial Chemical and Medical Raw Material Base Linhai Zone, Linhai City, Zhejiang Province, 317016, China.</paragraph>
                  <paragraph>Rev. 02/2025</paragraph>
               </text>
               <effectiveTime value="20250228"/>
            </section>
         </component>
         <component>
            <section ID="ID_d2f97c11-fabc-4161-9bc9-c742445d95ec">
               <id root="11757ff9-07dd-4e4e-af02-7066757e496b"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <colgroup>
                        <col width="100%"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule Toprule" align="center" valign="top">
                              <paragraph>
                                 <content styleCode="bold">PATIENT INFORMATION</content>
                              </paragraph>
                              <paragraph>Rosuvastatin tablets, USP<br/>(roe sooâ va statâ in)<br/>for oral use</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Read this Patient Information carefully before you start takingÂ rosuvastatin tablets and each time you get a refill. If you have any questions about rosuvastatin tablets, ask your healthcare provider. Only your healthcare provider can determine ifÂ rosuvastatin tablets are right for you.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are rosuvastatin tablets?</content>
                              </paragraph>
                              <paragraph>Rosuvastatin tablets are prescription medicines that contain a cholesterol-lowering medicine called rosuvastatin.<br/>â¢ Rosuvastatin tablets are used:<br/>o to reduce the risk of major adverse cardiovascular (CV) events, such as death from cardiovascular disease, heart attack, stroke, or the need for procedures to improve blood flow to the heart called arterial revascularization, in adults who do not have known heart disease but do have certain additional risk factors.<br/>o along with diet to:<br/>Â ÂºÂ lower the level of low-density lipoprotein (LDL-C) cholesterol or âbadâ cholesterol in adults with primary hyperlipidemia.<br/>Â ÂºÂ slow the buildup of fatty deposits (plaque) in the walls of blood vessels.<br/>Â ÂºÂ treat adults and children 8 years of age and older with high blood cholesterol due to heterozygous familial hypercholesterolemia (HeFH) (an inherited condition that causes high levels of LDL-C).<br/>o along with other cholesterol lowering treatments or alone if such treatments are unavailable in adults and children 7 years of age and older with homozygous familial hypercholesterolemia (HoFH) (an inherited condition that causes high levels of LDL-C).<br/>o along with diet for the treatment of adults with:<br/>Â ÂºÂ primary dysbetalipoproteinemia (an inherited condition that causes high levels of cholesterol and fat).<br/>Â ÂºÂ hypertriglyceridemia.</paragraph>
                              <paragraph>It is not known if rosuvastatin tablets are safe and effective in children younger than 8 years of age with HeFH or children younger than 7 years of age with HoFH or in children with other types of hyperlipidemias (other than HeFH or HoFH).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Do not takeÂ rosuvastatin tabletsÂ if you:</content>
                              </paragraph>
                              <paragraph>Â  Â  â¢Â  have liver problems.</paragraph>
                              <paragraph>Â  Â  â¢Â  are allergic to rosuvastatin or any of the ingredients in rosuvastatin tablets. See the end of this leaflet for a complete list of ingredients in rosuvastatin tablets.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before you take rosuvastatin tablets, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <paragraph>Â  Â â¢Â  have unexplained muscle aches or weakness.</paragraph>
                              <paragraph>Â  Â â¢Â  have or have had kidney problems.</paragraph>
                              <paragraph>Â  Â â¢Â  have or have had liver problems.</paragraph>
                              <paragraph>Â  Â â¢Â  drink more than 2 glasses of alcohol daily.</paragraph>
                              <paragraph>Â  Â â¢Â  have thyroid problems.</paragraph>
                              <paragraph>Â  Â â¢Â  are of Asian descent.</paragraph>
                              <paragraph>Â  Â â¢Â  are pregnant or think you may be pregnant, or are planning to become pregnant. If you become pregnant while taking rosuvastatin tablets, callÂ  your healthcare provider right away to discuss yourÂ rosuvastatin tablets treatment.</paragraph>
                              <paragraph>Â  Â â¢Â  are breastfeeding.Â Rosuvastatin tablets can pass into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take rosuvastatin tablets. Do not breastfeed while taking rosuvastatin tablets.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Tell your healthcare provider who prescribesÂ rosuvastatin tablets if another healthcare provider increases the dose of another medicine you are taking.Â Rosuvastatin tablets may affect the way other medicines work, and other medicines may affect howÂ rosuvastatin tablets works.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Especially tell your healthcare provider if you take:</paragraph>
                              <paragraph>Â  Â â¢Â  coumarin anticoagulants (medicines that prevent blood clots, such as warfarin)</paragraph>
                              <paragraph>Â  Â â¢Â  antacids (medicines you take for heartburn that contain aluminum and magnesium hydroxide</paragraph>
                              <paragraph>T<content>akingÂ rosuvastatin tablets with certain medicines may increase the risk of muscle problems.</content>
                              </paragraph>
                              <paragraph/>
                              <paragraph>Especially tell your healthcare provider if you take:</paragraph>
                              <paragraph>Â  Â â¢Â  cyclosporine (a medicine for your immune system)</paragraph>
                              <paragraph>Â  Â â¢Â  teriflunomide (a medicine used to treat relapsing remitting multiple sclerosis)</paragraph>
                              <paragraph>Â  Â â¢Â  enasidenib (a medicine used to treat acute myeloid leukemia)</paragraph>
                              <paragraph>Â  Â â¢Â  capmatinib (a medicine for the treatment of non-small cell lung cancer)</paragraph>
                              <paragraph>Â  Â â¢Â  fostamatinib (a medicine used to treat low platelet counts)</paragraph>
                              <paragraph>Â  Â â¢Â  febuxostat (a medicine used to treat and prevent high blood levels of uric acid)</paragraph>
                              <paragraph>Â  Â â¢Â  gemfibrozil (a fibric acid medicine for lowering cholesterol)</paragraph>
                              <paragraph>Â  Â â¢Â  tafamidis [used to treat cardiomyopathy (enlarged and thickened heart muscle)]</paragraph>
                              <paragraph>Â  Â â¢Â Â <content>anti-viral medicines including certain HIV or hepatitis C virus drugs such as:</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  Â  Â  ÂºÂ  Â lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir, simeprevir</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  Â  Â  ÂºÂ  Â combination of</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  Â  Â  Â  Â  Â âª sofosbuvir/velpatasvir/voxilaprevir</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  Â  Â  Â  Â  Â âª dasabuvir/ombitasvir/paritaprevir/ritonavir</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  Â  Â  Â  Â  Â âª elbasvir/grazoprevir</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  Â  Â  Â  Â  Â âª sofosbuvir/velpatasvir</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  Â  Â  Â  Â  Â âª glecaprevir/pibrentasvir<content styleCode="bold"> and</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  Â  Â Âº Â  all other combinations with ledipasvir including ledipasvir/sofosbuvir</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  â¢Â  darolutamide (a medicine for the treatment of prostate cancer)</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  â¢Â  regorafenib (a medicine used to treat cancer of the colon and rectum)</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  â¢Â  fibric acid derivatives (such as fenofibrate)</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  â¢Â  ticagrelor (helps reduce the chance of a blood clot formation that can block a blood vessel)</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  â¢Â  niacin or nicotinic acid</content>
                              </paragraph>
                              <paragraph>
                                 <content>Â  â¢Â  colchicine (a medicine used to treat gout)</content>
                              </paragraph>
                              <paragraph>Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I take rosuvastatin tablets?</content>
                              </paragraph>
                              <paragraph>Â  â¢Â  TakeÂ rosuvastatin tablets exactly as your healthcare provider tells you to take it.</paragraph>
                              <paragraph>Â  â¢Â  Take rosuvastatin tablets, by mouth, 1 time each day, with or without food. Swallow the tablet whole.</paragraph>
                              <paragraph>Â  â¢Â  Rosuvastatin tablets can be taken at any time of day, with or without food.</paragraph>
                              <paragraph>Â  â¢Â Â <content styleCode="bold">Do not</content> change your dose or stop rosuvastatin tabletswithout talking to your healthcare provider, even if you are feeling well.</paragraph>
                              <paragraph>Â  â¢Â  Your healthcare provider may do blood tests to check your cholesterol levels before and during your treatment with rosuvastatin tablets.Â  Â  Your healthcare provider may change your dose ofÂ rosuvastatin tablets if needed.</paragraph>
                              <paragraph>Â  â¢Â  While taking rosuvastatin tablets, continue to follow your cholesterol-lowering diet and to exercise as your healthcare provider told you to.</paragraph>
                              <paragraph>Â  â¢Â  If you take a medicine called an antacid that contains a combination of aluminum and magnesium hydroxide, takeÂ rosuvastatin tablets atÂ  least 2 hours before you take the antacid.</paragraph>
                              <paragraph>Â  â¢Â  If you miss a dose of rosuvastatin tablets, take your next dose at your normal scheduled time. <content styleCode="bold">Do not take </content>an extra dose of rosuvastatinÂ  tablets.</paragraph>
                              <paragraph>Â  â¢Â  In case of an overdose, get medical help or contact a live Poison Center expert right away at 1-800-222-1222. Advice is also availableÂ  Â  Â  online at poisonhelp.org.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of rosuvastatin tablets?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Rosuvastatin tabletsÂ may cause serious side effects, including:</content>
                              </paragraph>
                              <paragraph>Â  â¢Â Â <content styleCode="bold">Muscle pain, tenderness and weakness (myopathy).</content>Muscle problems, including muscle breakdown, can be serious in some people and rarely cause kidney damage that can lead to death. Tell your healthcare provider right away if:</paragraph>
                              <paragraph>Â  Â Âº Â you have unexplained muscle pain, tenderness, or weakness, especially if you have a fever or feel more tired than usual, while you take rosuvastatin tablets.</paragraph>
                              <paragraph>Â  Â Âº Â you have muscle problems that do not go away even after your healthcare provider has told you to stop taking rosuvastatin tablets. Your healthcare provider may do further tests to diagnose the cause of your muscle problems.</paragraph>
                              <paragraph>Your chances of getting muscle problems are higher if you:</paragraph>
                              <paragraph/>
                              <paragraph>Â  Â Âº Â are taking certain other medicines while you takeÂ rosuvastatin tablets (see âEspecially tell your healthcare provider if you takeâ)</paragraph>
                              <paragraph>Â  Â Âº Â are 65 years of age or older</paragraph>
                              <paragraph>Â  Â Âº Â are of Asian descent</paragraph>
                              <paragraph>Â  Â Âº Â have thyroid problems (hypothyroidism) that are not controlled</paragraph>
                              <paragraph>Â  Â ÂºÂ  have kidney problems</paragraph>
                              <paragraph>Â  Â Âº Â are taking higher doses ofÂ rosuvastatin tablets</paragraph>
                              <paragraph>Â  â¢Â Â <content styleCode="bold">Liver problems.</content>Your healthcare provider may do blood tests to check your liver before you start takingÂ rosuvastatin tablets and if you have symptoms of liver problems while you take rosuvastatin tablets. Call your healthcare provider right away if you have any of the following symptoms of liver problems:</paragraph>
                              <paragraph>Â  Â Âº Â feel unusually tired or weak</paragraph>
                              <paragraph>Â  Â Âº Â loss of appetite</paragraph>
                              <paragraph>Â  Â ÂºÂ  upper belly pain</paragraph>
                              <paragraph>Â  Â Âº Â dark urine</paragraph>
                              <paragraph>Â  Â Âº Â yellowing of your skin or the whites of your eyes</paragraph>
                              <paragraph>Â  â¢Â Â <content styleCode="bold">Protein and blood in the urine.</content>Â Rosuvastatin tabletsÂ may cause you to have protein and blood in your urine. If you develop protein or blood in your urine, your healthcare provider may decrease your dose of rosuvastatin tablets.</paragraph>
                              <paragraph>Â  â¢Â Â <content styleCode="bold">Increase in blood sugar (glucose) levels</content>. Rosuvastatin tabletsmay cause an increase in your blood sugar levels.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>The most common side effects may include headache, nausea, muscle aches and pains, weakness, and constipation.</paragraph>
                              <paragraph>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</paragraph>
                              <paragraph>For more information, ask your healthcare provider or pharmacist.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I store rosuvastatin tablets?</content>
                              </paragraph>Â  â¢Â  StoreÂ rosuvastatin tablets at room temperature, between 68Â°F to 77Â°F (20Â°C to 25Â°C) and in a dry place.<paragraph>
                                 <content styleCode="bold">KeepÂ rosuvastatin tablets and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">General Information about the safe and effective use ofÂ rosuvastatin tablets</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not useÂ rosuvastatin tablets for a condition for which it was not prescribed. Do not giveÂ rosuvastatin tablets to other people, even if they have the same medical condition you have. It may harm them.</paragraph>
                              <paragraph>You can ask your pharmacist or healthcare provider for information aboutÂ rosuvastatin tablets that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the Ingredients in rosuvastatin tablets?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active Ingredient:</content> rosuvastatin as rosuvastatin calcium</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive Ingredients:</content>Â microcrystalline cellulose NF, lactose monohydrate NF, anhydrous dibasic calcium phosphate USP, crospovidone NF, magnesium stearate NF, hypromellose USP, titanium dioxide USP, triacetin USP, yellow ferric oxide NF (rosuvastatin tablets, 5 mg and 20 mg), red ferric oxide NF (rosuvastatin tablets, 10 mg and 40 mg).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph>Rosuvastatin tablets are manufactured by Zhejiang Yongtai Pharmaceutical Co., Ltd.<br/>Zhejiang Yongtai Pharmaceutical Co., Ltd.<br/>No.1, 8th Donghai Avenue, Zhejiang Provincial Chemical and Medical Raw Material Base Linhai Zone, Linhai City, Zhejiang Province, 317016, China.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule" valign="top">
                              <paragraph>This Patient Information has been approved by the U.S. Food and Drug AdministrationÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Revised 02/2025</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20250228"/>
            </section>
         </component>
         <component>
            <section ID="ID_50a31cae-6e73-44ca-98a1-04cf054bb331">
               <id root="4025153f-49db-493c-850e-bad6109687cc"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel â 5 mg </title>
               <text>
                  <paragraph>NDC 69434-005-02<br/>Rosuvastatin<br/>Tablets<br/>5 mg<br/>Rx only<br/>90 Tablets<br/>Each tablet contains 5 mg of rosuvastatin (equivalent to 5.2 mg rosuvastatin calcium).</paragraph>
                  <paragraph>Recommended Dosage: See accompanying prescribing information.<br/>Warning: As with all medications, keep out of the reach of children.<br/>Store at controlled Room temperature,20Â° to 25Â°C (68Â° to 77Â°F);excursions permitted between 15Â°C and 30Â°C (59ÂºF and 86ÂºF).<br/>[See USP]. Protect from moisture.</paragraph>
                  <paragraph>Mfd. by: Zhejiang Yongtai Pharmaceutical Co., Ltd.<br/>No.1, 8th Donghai Avenue, Zhejiang Provincial Chemical and Medical Raw Material Base Linhai Zone, Linhai City, Zhejiang Province, 317016, China.</paragraph>
                  <renderMultiMedia referencedObject="DFF9EDB3-8989-4373-BE8E-54FD5D39156A"/>
               </text>
               <effectiveTime value="20250228"/>
               <component>
                  <observationMedia ID="DFF9EDB3-8989-4373-BE8E-54FD5D39156A">
                     <text>rosuvastatin tablet_5mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="rosuvastatintablet-5mg-90s.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3e08f84e-a534-4273-95cf-ca9f41d52084">
               <id root="a108dc32-7736-4b3f-9543-cc875dc83da4"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel â 10 mg </title>
               <text>
                  <paragraph>NDC 69434-006-02<br/>Rosuvastatin<br/>Tablets<br/>10 mg<br/>Rx only<br/>90 Tablets<br/>Each tablet contains 10 mg of rosuvastatin (equivalent to 10.4 mg rosuvastatin calcium).</paragraph>
                  <paragraph>Recommended Dosage: See accompanying prescribing information.<br/>Warning: As with all medications, keep out of the reach of children.<br/>Store at controlled Room temperature,20Â° to 25Â°C (68Â° to 77Â°F);excursions permitted between 15Â°C and 30Â°C (59ÂºF and 86ÂºF).<br/>[See USP]. Protect from moisture.</paragraph>
                  <paragraph>Mfd. by: Zhejiang Yongtai Pharmaceutical Co., Ltd.<br/>No.1, 8th Donghai Avenue, Zhejiang Provincial Chemical and Medical Raw Material Base Linhai Zone, Linhai City, Zhejiang Province, 317016, China.</paragraph>
                  <renderMultiMedia referencedObject="C321055B-115F-4FAC-AFC7-AB1F3F77D3ED"/>
               </text>
               <effectiveTime value="20250228"/>
               <component>
                  <observationMedia ID="C321055B-115F-4FAC-AFC7-AB1F3F77D3ED">
                     <text>rosuvastatin tablet_10mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="rosuvastatintablet-10mg-90s.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b0257fa1-61b3-40cb-a7ea-e3db2c2b6ccc">
               <id root="c1f6e02a-fc0c-4e25-8f42-af314411b691"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel â 20 mg </title>
               <text>
                  <paragraph>NDC 69434-007-02<br/>Rosuvastatin<br/>Tablets<br/>20 mg<br/>Rx only<br/>90 Tablets<br/>Each tablet contains 20 mg of rosuvastatin (equivalent to 20.8 mg rosuvastatin calcium).</paragraph>
                  <paragraph>Recommended Dosage: See accompanying prescribing information.<br/>Warning: As with all medications, keep out of the reach of children.<br/>Store at controlled Room temperature,20Â° to 25Â°C (68Â° to 77Â°F);excursions permitted between 15Â°C and 30Â°C (59ÂºF and 86ÂºF).<br/>[See USP]. Protect from moisture.</paragraph>
                  <paragraph>Mfd. by: Zhejiang Yongtai Pharmaceutical Co., Ltd.<br/>No.1, 8th Donghai Avenue, Zhejiang Provincial Chemical and Medical Raw Material Base Linhai Zone, Linhai City, Zhejiang Province, 317016, China.</paragraph>
                  <renderMultiMedia referencedObject="ID_6a0d2450-988e-4012-9e14-168d29e88f5e"/>
               </text>
               <effectiveTime value="20250228"/>
               <component>
                  <observationMedia ID="ID_6a0d2450-988e-4012-9e14-168d29e88f5e">
                     <text>rosuvastatin tablet_20mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="rosuvastatintablet-20mg-90s.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9edc4f6f-26a2-424d-99a4-f6365dc336e7">
               <id root="3c19ff4b-6ae9-43fc-995a-b43b986fd468"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel â 40 mg </title>
               <text>
                  <paragraph>NDC 69434-008-01<br/>Rosuvastatin<br/>Tablets<br/>40 mg<br/>Rx only<br/>90 Tablets<br/>Each tablet contains 40 mg of rosuvastatin (equivalent to 41.6 mg rosuvastatin calcium).</paragraph>
                  <paragraph>Recommended Dosage: See accompanying prescribing information.<br/>Warning: As with all medications, keep out of the reach of children.<br/>Store at controlled Room temperature,20Â° to 25Â°C (68Â° to 77Â°F);excursions permitted between 15Â°C and 30Â°C (59ÂºF and 86ÂºF).<br/>[See USP]. Protect from moisture.</paragraph>
                  <paragraph>Mfd. by: Zhejiang Yongtai Pharmaceutical Co., Ltd.<br/>No.1, 8th Donghai Avenue, Zhejiang Provincial Chemical and Medical Raw Material Base Linhai Zone, Linhai City, Zhejiang Province, 317016, China.</paragraph>
                  <renderMultiMedia referencedObject="ID_4d4c2d5b-14e7-4678-8931-9f899fbb088f"/>
               </text>
               <effectiveTime value="20250228"/>
               <component>
                  <observationMedia ID="ID_4d4c2d5b-14e7-4678-8931-9f899fbb088f">
                     <text>rosuvastatin tablet_40mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="rosuvastatintablet-40mg-30s.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>